http://wiki.metabolomicssociety.org/api.php?action=feedcontributions&user=FitriAmalia&feedformat=atomMetabolomics Society Wiki - User contributions [en]2024-03-28T09:46:35ZUser contributionsMediaWiki 1.28.0http://wiki.metabolomicssociety.org/index.php?title=Main_Page&diff=1674Main Page2022-07-20T14:58:17Z<p>FitriAmalia: </p>
<hr />
<div>__NOTOC____NOEDITSECTION__{{notitle}}<div style="position: relative; top: -30px; z-index: 100; font-size:100%;"><br />
{|cellpadding="5" cellspacing="0"|<br />
<br />
|style="border: 1px solid #DDDDDD;font-size:120%"|<br />
Welcome to the '''Early-Career Members Network (EMN) Webpage''', a resource curated by [[Early-Career_Members_Network | Early-Career Members Network of the Metabolomics Society]]. This wiki-styled page is designed to be a focal point for educational resources and online tools related to all facets of metabolomics, aiming to reach mainly young researchers of the field.<br />
<br />
<!-- NOTES FOR THE CATEGORIES TABLE:<br />
<br />
* There is *NO* paragraph break after the <br /> tags, only a single space.<br />
* Do not enter empty lines anywhere between <span...> and </center> (breaks the formatting).<br />
* Images are taken from http://en.wikipedia.org/wiki/Wikipedia:Categorical_index<br />
<br />
<br />
--><br />
<span id="Highlights"></span><br />
<center><br />
<br />
{| width=90% style="border: 2px solid #DDDDDD; background-color:rgb(250,250,255); margin-top:10px" cellspacing=20<br />
!colspan=2 style="text-align:center; font-size:100%;"|'''Highlights'''<br />
|-<br />
!colspan=2 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;padding-left:1em;"|<br />
<h3><br />
[[Image: RueyLengLoo.jpg|x140px|border|link= Ruey Leng Loo]]<br /><br /> <br />
This month Expert Opinion comes from Dr. [[Ruey Leng Loo| Ruey Leng Loo!]]<br /><br /><br />
</h3><br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;"|<br />
<h3><br />
[[Image:Conference_2022.png|x150px|border|link=Upcoming Events]]<br /><br /> <br />
Do not miss the Metabolomics Conference 2022. Click [https://www.metabolomics2022.org/ here] to know more! <br /><br /><br />
|}<br />
<br />
<span id="Regions"></span><br />
<br />
{|width=80% style="border: 2px solid #DDDDDD; margin-top:1px" cellspacing=1;"<br />
!colspan=6 style="text-align:center; font-size:100%;"|'''Finding Metabolomics Communities'''<br />
|-<br />
!colspan=6 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:16,66%; font-size:95%; vertical-align:bottom; text-align:center;"|<br />
[[Image:128px-Blank Map-Africa.svg.png|link= Metabolomics Communities#Africa|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Africa|'''Africa''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-Location Map Asia.svg.png|link= Metabolomics Communities#Asia|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Asia|'''Asia''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:BlankMap-Europe-v4.png|link= Metabolomics Communities#Europe|x100px]]<br /><br /><br />
[[Metabolomics_Communities#Europe|'''Europe''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-America_Blank.svg.png|link=Metabolomics Communities#North and Central America|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#North and Central America|'''North & Central America''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:Blank Map Oceania3.svg.png|link=Metabolomics Communities#Oceania|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Oceania|'''Oceania''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-BlankMap-South-America.png|link= Communities#South America|x100px]]<br /><br /><br />
[[Metabolomics_Communities#South America|'''South America''']] <br /><br /> <br />
|}<br />
<br />
<span id="Keep updated! Follow us"></span><br />
{| width=90% style="border: 2px solid #DDDDDD; ; margin-top:20px" cellspacing=6<br />
!colspan=3 style="text-align:center; font-size:100%;"|'''Keep updated! Follow us on social medias!'''<br />
|-<br />
!colspan=3 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:right; padding-left:1em;"|<br />
[[Image: Facebook.png|70px|link=https://www.facebook.com/EMN.MetabolomicsSociety]]<br /><br /> <br />
|style="width:20%; font-size:95%; vertical-align:center; text-align:left;"|<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:left;"|<br />
[[Image:Twitter.png|70px|link=https://twitter.com/emn_metsoc?lang=pt]]<br /><br /> <br />
</h3><br />
|}<br />
If you would like to suggest content, please contact the current EMN committee at ''info.emn@metabolomicssociety.org''<br />
|}</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1673Ruey Leng Loo2022-07-18T12:37:54Z<p>FitriAmalia: /* References */</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Ruey Leng Loo completed a PhD in metabolic phenotyping at the Imperial College, London. After that, she was appointed as a Lecturer and was subsequently promoted to Senior Lecturer in 2017. She moved to Murdoch University in 2019 having secured a Western Australia Premier’s Science Mid-Career Fellowship.<br />
<br />
Ruey Leng’s research focuses on biomarkers discovery in cardiovascular disease (CVD), and because the major contributing risk factors of CVD are largely affected by modifiable risk factors such as poor diet, she has also expanded her research interest to interrogate foods/food products that we eat and assess how foods affect human health a molecular level.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started using metabolomics during my PhD study in 2004 at the Imperial College London. The project applied NMR- based metabolomics to better understand the influence of diets on blood pressure. Prior to my PhD, I had no experience in metabolomics but my background in pharmacy and interest in gaining a better understanding on why people respond differently to diets and medications pique my interest in the field.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
My primary research focus remains on applying the metabolome-wide association approach to investigate cardiovascular disease risk using both population and clinical intervention studies. Since moving to the Australian National Phenome Centre (ANPC), Murdoch University in 2019, I have further expanded my research focus to include the analysis of food. I deeply characterise food compositions by leveraging the multiple analytical platforms available at the ANPC to understand the molecular basis of healthy nutrition, and ultimately connect nutritional quality and composition with positive healthcare outcomes through nutritional health claims. My research goal, therefore, aims to enable future preventative medicine strategies at the individual and population levels.<br />
<br />
===Question 3===<br />
<br />
''' 3. You contributed to the development of the metabolome-wide association study (MWAS) approaches to molecular phenotyping, what are the biggest challenges in this field and how did you overcome that? '''<br />
<br />
At the time, it was the first time metabolomics was used to analyse thousands of samples from a cross-sectional population study. The challenge is to identify a suitable data analysis strategy to unpick the subtle changes in the metabolic phenotypes and to understand the biological meaning behind these changes (and of course including the identification of the unknown metabolites). I was lucky to have good mentors so I was able to discuss these challenges with them and address them methodically.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are also involved in the development of metabolic phenotyping methodologies, including the use of alternative sampling methodologies such as dried blood spots. What are the challenges that you face when developing such methodologies and what would you say are the main advantages? '''<br />
<br />
This is the same with developing any other new methodology. We need to consider all aspects, from sampling protocol to extraction, and instrumentation optimisation. In my view, the application of metabolic phenotyping approaches in dried blood spot samples offers the opportunity to perform this in remote, low-resource settings where the collection and storage of serum/plasma are challenging. Together with my collaborators, we have demonstrated that this is possible [1]. Furthermore, this phenotyping technique also offers the option for profiling neonates and/or small children where a large volume of blood collection is often not feasible.<br />
<br />
===Question 5===<br />
<br />
''' 5. Regarding your recent studies on the COVID19 disease, would you mind sharing your valuable findings with the community? '''<br />
<br />
Together with colleagues at the ANPC, we are working on multiple cohorts of COVID-19 samples. So far, we have shown plasma cytokines are useful indicators of a patient’s response to cellular immune response to SARS-CoV-2 infection. However, monitoring these immune responses interacting with the plasma lipoproteins and small molecule metabolites has highlighted the incomplete systemic recovery despite symptoms related to the infection has fully subsided [2]. Moreover, we have also shown the lipoprotein bound phospholipids, which we called SPC, are reduced during SARS-CoV-2 infection and that the SPC has been linked to cardiovascular disease risk [3].<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers who are interested in applying MWAS approaches in their research? '''<br />
<br />
There are many aspects to consider here but my suggestion would be to understand the analytical techniques that you want to use, consider the pros and cons of using them, and clearly define the study aims in your chosen study area. Once you have a clear idea of what you want to do, speak to other researchers or your mentors as they can help you to shape your project design and prevent you from repeating the same mistake!<br />
<br />
<br />
===References===<br />
<br />
1. Loo, R.L., Lu, Q., Carter, E.M. et al. A feasibility study of metabolic phenotyping of dried blood spot specimens in rural Chinese women exposed to household air pollution. J Expo Sci Environ Epidemiol 31, 328–344 (2021). https://doi.org/10.1038/s41370-020-0252-0<br />
<br />
2. Lodge, Samantha, et al. Low volume in vitro diagnostic proton NMR spectroscopy of human blood plasma for lipoprotein and metabolite analysis: application to SARS-CoV-2 biomarkers. Journal of proteome research 20.2 (2021): 1415-1423. https://doi.org/10.1021/acs.jproteome.0c00815<br />
<br />
3. Masuda, Reika, et al. Exploration of Human Serum Lipoprotein Supramolecular Phospholipids Using Statistical Heterospectroscopy in n-Dimensions (SHY-n): Identification of Potential Cardiovascular Risk Biomarkers Related to SARS-CoV-2 Infection. Analytical Chemistry 94.10 (2022): 4426-4436. https://doi.org/10.1021/acs.analchem.1c05389<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1672Ruey Leng Loo2022-07-18T12:36:11Z<p>FitriAmalia: /* Expert Opinion */</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Ruey Leng Loo completed a PhD in metabolic phenotyping at the Imperial College, London. After that, she was appointed as a Lecturer and was subsequently promoted to Senior Lecturer in 2017. She moved to Murdoch University in 2019 having secured a Western Australia Premier’s Science Mid-Career Fellowship.<br />
<br />
Ruey Leng’s research focuses on biomarkers discovery in cardiovascular disease (CVD), and because the major contributing risk factors of CVD are largely affected by modifiable risk factors such as poor diet, she has also expanded her research interest to interrogate foods/food products that we eat and assess how foods affect human health a molecular level.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started using metabolomics during my PhD study in 2004 at the Imperial College London. The project applied NMR- based metabolomics to better understand the influence of diets on blood pressure. Prior to my PhD, I had no experience in metabolomics but my background in pharmacy and interest in gaining a better understanding on why people respond differently to diets and medications pique my interest in the field.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
My primary research focus remains on applying the metabolome-wide association approach to investigate cardiovascular disease risk using both population and clinical intervention studies. Since moving to the Australian National Phenome Centre (ANPC), Murdoch University in 2019, I have further expanded my research focus to include the analysis of food. I deeply characterise food compositions by leveraging the multiple analytical platforms available at the ANPC to understand the molecular basis of healthy nutrition, and ultimately connect nutritional quality and composition with positive healthcare outcomes through nutritional health claims. My research goal, therefore, aims to enable future preventative medicine strategies at the individual and population levels.<br />
<br />
===Question 3===<br />
<br />
''' 3. You contributed to the development of the metabolome-wide association study (MWAS) approaches to molecular phenotyping, what are the biggest challenges in this field and how did you overcome that? '''<br />
<br />
At the time, it was the first time metabolomics was used to analyse thousands of samples from a cross-sectional population study. The challenge is to identify a suitable data analysis strategy to unpick the subtle changes in the metabolic phenotypes and to understand the biological meaning behind these changes (and of course including the identification of the unknown metabolites). I was lucky to have good mentors so I was able to discuss these challenges with them and address them methodically.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are also involved in the development of metabolic phenotyping methodologies, including the use of alternative sampling methodologies such as dried blood spots. What are the challenges that you face when developing such methodologies and what would you say are the main advantages? '''<br />
<br />
This is the same with developing any other new methodology. We need to consider all aspects, from sampling protocol to extraction, and instrumentation optimisation. In my view, the application of metabolic phenotyping approaches in dried blood spot samples offers the opportunity to perform this in remote, low-resource settings where the collection and storage of serum/plasma are challenging. Together with my collaborators, we have demonstrated that this is possible [1]. Furthermore, this phenotyping technique also offers the option for profiling neonates and/or small children where a large volume of blood collection is often not feasible.<br />
<br />
===Question 5===<br />
<br />
''' 5. Regarding your recent studies on the COVID19 disease, would you mind sharing your valuable findings with the community? '''<br />
<br />
Together with colleagues at the ANPC, we are working on multiple cohorts of COVID-19 samples. So far, we have shown plasma cytokines are useful indicators of a patient’s response to cellular immune response to SARS-CoV-2 infection. However, monitoring these immune responses interacting with the plasma lipoproteins and small molecule metabolites has highlighted the incomplete systemic recovery despite symptoms related to the infection has fully subsided [2]. Moreover, we have also shown the lipoprotein bound phospholipids, which we called SPC, are reduced during SARS-CoV-2 infection and that the SPC has been linked to cardiovascular disease risk [3].<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers who are interested in applying MWAS approaches in their research? '''<br />
<br />
There are many aspects to consider here but my suggestion would be to understand the analytical techniques that you want to use, consider the pros and cons of using them, and clearly define the study aims in your chosen study area. Once you have a clear idea of what you want to do, speak to other researchers or your mentors as they can help you to shape your project design and prevent you from repeating the same mistake!<br />
<br />
<br />
===References===<br />
<br />
1. Loo, R.L., Lu, Q., Carter, E.M. et al. A feasibility study of metabolic phenotyping of dried blood spot specimens in rural Chinese women exposed to household air pollution. J Expo Sci Environ Epidemiol 31, 328–344 (2021). https://doi.org/10.1038/s41370-020-0252-0<br />
<br />
2. Lodge, Samantha, et al. "Low volume in vitro diagnostic proton NMR spectroscopy of human blood plasma for lipoprotein and metabolite analysis: application to SARS-CoV-2 biomarkers." Journal of proteome research 20.2 (2021): 1415-1423.<br />
<br />
3. Masuda, Reika, et al. "Exploration of Human Serum Lipoprotein Supramolecular Phospholipids Using Statistical Heterospectroscopy in n-Dimensions (SHY-n): Identification of Potential Cardiovascular Risk Biomarkers Related to SARS-CoV-2 Infection." Analytical Chemistry 94.10 (2022): 4426-4436.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Tim_Ebbels&diff=1671Tim Ebbels2022-07-18T12:24:15Z<p>FitriAmalia: /* References */</p>
<hr />
<div>[[Image: TimEbbels.jpg|thumb| Tim Ebbels ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Prof Tim Ebbels obtained his PhD in astrophysics from the University of Cambridge and in 1998 moved into bioinformatics via postdoctoral work at Imperial College London. His group focuses on the application of bioinformatic, machine learning and chemometric techniques to post-genomic data, with a particular emphasis on computational metabolomics. He has worked on projects ranging from environmental monitoring, through molecular epidemiology, to toxicogenomics and high-performance computing infrastructures. Much work focuses on modelling of the analytical technologies used to obtain metabolomic data, but his group is also addressing problems of data integration, visualisation, network analysis, time series and metabolite annotation. He is particularly known for the ‘BATMAN’ software for analysing complex metabolic NMR spectra. Tim is an active member of the metabolomics community, having served as a Director of the international Metabolomics Society from 2012-2018 (Secretary from 2014-16). He has co-organised several international conferences (international scientific committee Metabolomics 2014-17) and is a co-founder of the London Metabolomics Network. He is a member of the OECD Metabolomics Reporting Framework, co-chaired the ECETOC Metabolomics Standards Initiative in Toxicology (MERIT) and is an editorial board member for BMC Bioinformatics and the Journal of Chemometrics. He has a strong commitment to postgraduate education, serving as Director of the MRes in Biomedical Research at Imperial College (>700 students trained), leading its Data Science stream and leading the Data Analysis short course at the Imperial’s International Phenome Training Centre. He is a Fellow of the Royal Society of Chemistry.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I got into metabolomics before the name existed! Having done a PhD in astrophysics, I was bored with my job in commerce and was looking for an academic challenge. In October 1998 joined the group of Jeremy Nicholson and John Lindon to apply maximum entropy techniques to extract signals from NMR spectra of biofluids. I realised that extracting information from complex mixtures was a really interesting and challenging problem, to which I could apply the skills I had learnt in physics. Actually, analysing NMR spectra of biological samples is not so very different from analysing optical spectra of distant galaxies! I also found that the world of metabolomics (and omics more generally) was fascinating and contained a host of intriguing but unsolved problems. I started to learn more about machine learning and multivariate statistics and enjoyed the idea that these approaches could be applied to attack problems in biological and biomedical research. I could see that these computational approaches would only become more important in disentangling the molecular data which was becoming ever larger and more complex, so I decided to stay in the field.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
As usual I’m involved in a variety of projects both developing new methods and applying them to real problems. One of my strong interests is data integration. While most people think of multi-omics integration, in my view this topic is much broader. For example, one can think of combining untargeted datasets collected with similar assays but on different samples. How can you match metabolomic features (e.g. defined by m/z and retention time, RT) without knowing the metabolite identities? Rui Pinto from Imperial’s School of Public Health has developed some exciting network based methods for solving this problem beyond simple “nearest neighbour” matching. Since metabolomics often combines data from multiple assays on the same samples, one can also ask how these should be combined in statistical models. We’ve worked in this area before using multi-block PLS and other methods to produce integrative predictive models. Another area which is relatively new to me is computational annotation of metabolomic datasets. This means putting an identity on an unknown peak, though usually not with 100% certainty. We are involved in a project with Rick Dunn (Liverpool University) and Claire O’donovan (European Bioinformatics Institute) which aims to annotate unknown compounds in the EBI’s Metabolights database to enrich and add value to existing data. A new project starting soon will add in Prof Pieter Dorrestein and the GNPS database to aid in this effort. Other areas of current interest include development of pathway based tools to model and integrate data. We have found that pathway based analysis of metabolomic data is far from straightforward [1] but still feel that there is great potential to use these methods for data fusion as they naturally map entities from different omic domains to a common space, and are highly interpretable.<br />
<br />
===Question 3===<br />
<br />
''' 3. Integrating data from different -omic technologies can be challenging, what is the biggest obstacle that you need to overcome before you can synthesise information from multi-omic datasets? '''<br />
<br />
I think perhaps the biggest challenge is actually defining what you are aiming at by integrating multi-omic data. Are you looking to find new relationships between molecules? Or are you aiming to make better predictions? Or is a mechanistic understanding you are aiming at? Depending on these goals, the best type of analysis will change. Beyond this, of course the big challenges are things like identification of unknown metabolites, the difficulty of mapping metabolites to known pathways and the huge mismatch between different -omes in their dimensionality, scale and noise characteristics. This all assumes that the same samples have been assayed in the different omics, i.e. the samples are matched. If however, different samples have been used in the different omics (e.g. separate biological replicates for metabolomics and transcriptomics) then you will need to take a different approach, perhaps by comparing average profiles in each condition. Overall, there are many challenges which depend on the experimental design and assay types.<br />
<br />
===Question 4===<br />
<br />
''' 4. Are there specific resources for computational metabolomics that you would recommend beginners for statistical integration and visualisation of metabolic profiles and networks with other post-omic data? '''<br />
<br />
There are some great tools out there. A good place to start could be our recently published a Nature Protocols workflow for conventional statistical analysis in metabolomics [2]. This uses a set of iPython notebooks to model the metabolomic data and includes univariate and multivariate statistical methods. But there are many other tools, both open source and commercial. Metaboanalyst, for example, is a free online environment offering a very wide range of tools, for data analysis. But one has to be careful when using these – or any tools. You must be sure you understand the method being applied and its strengths and weaknesses. This is particularly true of web-based tools which make it extremely easy to produce outputs which could be biased or inappropriate.<br />
<br />
===Question 5===<br />
<br />
''' 5. You have developed various tools for interpreting data for multi-omic experiments, like IMPaLA. Are there guidelines for researchers in the field to use such tools? '''<br />
<br />
I think multi-omic modelling is still in its infancy. There are so many different types of study aims, omics data and experimental design that it is hard to come up with harmonised approaches to integrate and interpret the results. Pathway tools like IMPaLA are great, and present a common framework onto which we can map – in principle – any omic data. As yet, there are limited guidelines for use of these, though we and others are working on it [1][3]. There are exciting developments in this area such as single sample pathway methods which allow any omic data to be transformed into a “pathway space” where one can then conduct any type of statistical or machine learning model. This goes beyond just a list of enriched pathways, allowing researchers, for example, to compare more than two classes, compare individual sample pathway scores, or visualise networks of pathways. Many of these approaches were first developed for transcriptomics data and their use in metabolomics can be both powerful and highly problematic. We are currently investigating how they can be safely used to integrate metabolomic and other omics data – watch this space!<br />
<br />
===Question 6===<br />
''' 6. Do you have any advice for early career members working in the field of computational metabolomics?'''<br />
<br />
My primary advice for anyone starting off in computational metabolomics would be to get a thorough understanding of the analytical technology and procedures first. This is important, of course, for understanding the problems in the field, and deciding which to prioritise. But it is even more important to be able to communicate with researchers from other disciplines – especially those of “traditional” analytical chemistry and biology. Only by speaking the same language can one build productive partnerships which yield advances in this area. If you have a more computational training, it can help a lot to base yourself within a group which generates its own analytical data. This way you get to talk to people facing these problems every day and can learn a great deal from their complementary knowledge.<br />
<br />
===References===<br />
1. Wieder C, Frainay C, Poupin N, Rodríguez-Mier P, Vinson F, et al. (2021). Pathway analysis in metabolomics: Recommendations for the use of over-representation analysis. PLOS Computational Biology 17(9): e1009105. https://doi.org/10.1371/journal.pcbi.1009105<br />
<br />
2. Blaise, B.J., Correia, G.D.S., Haggart, G.A. et al. (2021). Statistical analysis in metabolic phenotyping. Nat Protoc 16, 4299–4326 (2021). https://doi.org/10.1038/s41596-021-00579-1<br />
<br />
3. Khatri, P., Sirota, M., & Butte, A. J. (2012). Ten years of pathway analysis: current approaches and outstanding challenges. PLoS computational biology, 8(2), e1002375. https://doi.org/10.1371/journal.pcbi.1002375<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1670Ruey Leng Loo2022-07-18T12:23:41Z<p>FitriAmalia: /* Question 6 */</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Ruey Leng Loo completed a PhD in metabolic phenotyping at the Imperial College, London. After that, she was appointed as a Lecturer and was subsequently promoted to Senior Lecturer in 2017. She moved to Murdoch University in 2019 having secured a Western Australia Premier’s Science Mid-Career Fellowship.<br />
<br />
Ruey Leng’s research focuses on biomarkers discovery in cardiovascular disease (CVD), and because the major contributing risk factors of CVD are largely affected by modifiable risk factors such as poor diet, she has also expanded her research interest to interrogate foods/food products that we eat and assess how foods affect human health a molecular level.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started using metabolomics during my PhD study in 2004 at the Imperial College London. The project applied NMR- based metabolomics to better understand the influence of diets on blood pressure. Prior to my PhD, I had no experience in metabolomics but my background in pharmacy and interest in gaining a better understanding on why people respond differently to diets and medications pique my interest in the field.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
My primary research focus remains on applying the metabolome-wide association approach to investigate cardiovascular disease risk using both population and clinical intervention studies. Since moving to the Australian National Phenome Centre (ANPC), Murdoch University in 2019, I have further expanded my research focus to include the analysis of food. I deeply characterise food compositions by leveraging the multiple analytical platforms available at the ANPC to understand the molecular basis of healthy nutrition, and ultimately connect nutritional quality and composition with positive healthcare outcomes through nutritional health claims. My research goal, therefore, aims to enable future preventative medicine strategies at the individual and population levels.<br />
<br />
===Question 3===<br />
<br />
''' 3. You contributed to the development of the metabolome-wide association study (MWAS) approaches to molecular phenotyping, what are the biggest challenges in this field and how did you overcome that? '''<br />
<br />
At the time, it was the first time metabolomics was used to analyse thousands of samples from a cross-sectional population study. The challenge is to identify a suitable data analysis strategy to unpick the subtle changes in the metabolic phenotypes and to understand the biological meaning behind these changes (and of course including the identification of the unknown metabolites). I was lucky to have good mentors so I was able to discuss these challenges with them and address them methodically.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are also involved in the development of metabolic phenotyping methodologies, including the use of alternative sampling methodologies such as dried blood spots. What are the challenges that you face when developing such methodologies and what would you say are the main advantages? '''<br />
<br />
This is the same with developing any other new methodology. We need to consider all aspects, from sampling protocol to extraction, and instrumentation optimisation. In my view, the application of metabolic phenotyping approaches in dried blood spot samples offers the opportunity to perform this in remote, low-resource settings where the collection and storage of serum/plasma are challenging. Together with my collaborators, we have demonstrated that this is possible (Loo et al J Expo Sci Environ Epidemiol 2021; 31(2):328-244). Furthermore, this phenotyping technique also offers the option for profiling neonates and/or small children where a large volume of blood collection is often not feasible.<br />
<br />
===Question 5===<br />
<br />
''' 5. Regarding your recent studies on the COVID19 disease, would you mind sharing your valuable findings with the community? '''<br />
<br />
Together with colleagues at the ANPC, we are working on multiple cohorts of COVID-19 samples. So far, we have shown plasma cytokines are useful indicators of a patient’s response to cellular immune response to SARS-CoV-2 infection. However, monitoring these immune responses interacting with the plasma lipoproteins and small molecule metabolites has highlighted the incomplete systemic recovery despite symptoms related to the infection has fully subsided (Lodge et al Journal of Proteome Research 2021; 20 (2): 1382-1396). Moreover, we have also shown the lipoprotein bound phospholipids, which we called SPC, are reduced during SARS-CoV-2 infection and that the SPC has been linked to cardiovascular disease risk (Masuda et al Anal Chem 2022; 94(10):4426-4436).<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers who are interested in applying MWAS approaches in their research? '''<br />
<br />
There are many aspects to consider here but my suggestion would be to understand the analytical techniques that you want to use, consider the pros and cons of using them, and clearly define the study aims in your chosen study area. Once you have a clear idea of what you want to do, speak to other researchers or your mentors as they can help you to shape your project design and prevent you from repeating the same mistake!<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1669Ruey Leng Loo2022-07-18T12:22:58Z<p>FitriAmalia: /* Question 5 */</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Ruey Leng Loo completed a PhD in metabolic phenotyping at the Imperial College, London. After that, she was appointed as a Lecturer and was subsequently promoted to Senior Lecturer in 2017. She moved to Murdoch University in 2019 having secured a Western Australia Premier’s Science Mid-Career Fellowship.<br />
<br />
Ruey Leng’s research focuses on biomarkers discovery in cardiovascular disease (CVD), and because the major contributing risk factors of CVD are largely affected by modifiable risk factors such as poor diet, she has also expanded her research interest to interrogate foods/food products that we eat and assess how foods affect human health a molecular level.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started using metabolomics during my PhD study in 2004 at the Imperial College London. The project applied NMR- based metabolomics to better understand the influence of diets on blood pressure. Prior to my PhD, I had no experience in metabolomics but my background in pharmacy and interest in gaining a better understanding on why people respond differently to diets and medications pique my interest in the field.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
My primary research focus remains on applying the metabolome-wide association approach to investigate cardiovascular disease risk using both population and clinical intervention studies. Since moving to the Australian National Phenome Centre (ANPC), Murdoch University in 2019, I have further expanded my research focus to include the analysis of food. I deeply characterise food compositions by leveraging the multiple analytical platforms available at the ANPC to understand the molecular basis of healthy nutrition, and ultimately connect nutritional quality and composition with positive healthcare outcomes through nutritional health claims. My research goal, therefore, aims to enable future preventative medicine strategies at the individual and population levels.<br />
<br />
===Question 3===<br />
<br />
''' 3. You contributed to the development of the metabolome-wide association study (MWAS) approaches to molecular phenotyping, what are the biggest challenges in this field and how did you overcome that? '''<br />
<br />
At the time, it was the first time metabolomics was used to analyse thousands of samples from a cross-sectional population study. The challenge is to identify a suitable data analysis strategy to unpick the subtle changes in the metabolic phenotypes and to understand the biological meaning behind these changes (and of course including the identification of the unknown metabolites). I was lucky to have good mentors so I was able to discuss these challenges with them and address them methodically.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are also involved in the development of metabolic phenotyping methodologies, including the use of alternative sampling methodologies such as dried blood spots. What are the challenges that you face when developing such methodologies and what would you say are the main advantages? '''<br />
<br />
This is the same with developing any other new methodology. We need to consider all aspects, from sampling protocol to extraction, and instrumentation optimisation. In my view, the application of metabolic phenotyping approaches in dried blood spot samples offers the opportunity to perform this in remote, low-resource settings where the collection and storage of serum/plasma are challenging. Together with my collaborators, we have demonstrated that this is possible (Loo et al J Expo Sci Environ Epidemiol 2021; 31(2):328-244). Furthermore, this phenotyping technique also offers the option for profiling neonates and/or small children where a large volume of blood collection is often not feasible.<br />
<br />
===Question 5===<br />
<br />
''' 5. Regarding your recent studies on the COVID19 disease, would you mind sharing your valuable findings with the community? '''<br />
<br />
Together with colleagues at the ANPC, we are working on multiple cohorts of COVID-19 samples. So far, we have shown plasma cytokines are useful indicators of a patient’s response to cellular immune response to SARS-CoV-2 infection. However, monitoring these immune responses interacting with the plasma lipoproteins and small molecule metabolites has highlighted the incomplete systemic recovery despite symptoms related to the infection has fully subsided (Lodge et al Journal of Proteome Research 2021; 20 (2): 1382-1396). Moreover, we have also shown the lipoprotein bound phospholipids, which we called SPC, are reduced during SARS-CoV-2 infection and that the SPC has been linked to cardiovascular disease risk (Masuda et al Anal Chem 2022; 94(10):4426-4436).<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1668Ruey Leng Loo2022-07-18T12:21:53Z<p>FitriAmalia: /* Question 4 */</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Ruey Leng Loo completed a PhD in metabolic phenotyping at the Imperial College, London. After that, she was appointed as a Lecturer and was subsequently promoted to Senior Lecturer in 2017. She moved to Murdoch University in 2019 having secured a Western Australia Premier’s Science Mid-Career Fellowship.<br />
<br />
Ruey Leng’s research focuses on biomarkers discovery in cardiovascular disease (CVD), and because the major contributing risk factors of CVD are largely affected by modifiable risk factors such as poor diet, she has also expanded her research interest to interrogate foods/food products that we eat and assess how foods affect human health a molecular level.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started using metabolomics during my PhD study in 2004 at the Imperial College London. The project applied NMR- based metabolomics to better understand the influence of diets on blood pressure. Prior to my PhD, I had no experience in metabolomics but my background in pharmacy and interest in gaining a better understanding on why people respond differently to diets and medications pique my interest in the field.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
My primary research focus remains on applying the metabolome-wide association approach to investigate cardiovascular disease risk using both population and clinical intervention studies. Since moving to the Australian National Phenome Centre (ANPC), Murdoch University in 2019, I have further expanded my research focus to include the analysis of food. I deeply characterise food compositions by leveraging the multiple analytical platforms available at the ANPC to understand the molecular basis of healthy nutrition, and ultimately connect nutritional quality and composition with positive healthcare outcomes through nutritional health claims. My research goal, therefore, aims to enable future preventative medicine strategies at the individual and population levels.<br />
<br />
===Question 3===<br />
<br />
''' 3. You contributed to the development of the metabolome-wide association study (MWAS) approaches to molecular phenotyping, what are the biggest challenges in this field and how did you overcome that? '''<br />
<br />
At the time, it was the first time metabolomics was used to analyse thousands of samples from a cross-sectional population study. The challenge is to identify a suitable data analysis strategy to unpick the subtle changes in the metabolic phenotypes and to understand the biological meaning behind these changes (and of course including the identification of the unknown metabolites). I was lucky to have good mentors so I was able to discuss these challenges with them and address them methodically.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are also involved in the development of metabolic phenotyping methodologies, including the use of alternative sampling methodologies such as dried blood spots. What are the challenges that you face when developing such methodologies and what would you say are the main advantages? '''<br />
<br />
This is the same with developing any other new methodology. We need to consider all aspects, from sampling protocol to extraction, and instrumentation optimisation. In my view, the application of metabolic phenotyping approaches in dried blood spot samples offers the opportunity to perform this in remote, low-resource settings where the collection and storage of serum/plasma are challenging. Together with my collaborators, we have demonstrated that this is possible (Loo et al J Expo Sci Environ Epidemiol 2021; 31(2):328-244). Furthermore, this phenotyping technique also offers the option for profiling neonates and/or small children where a large volume of blood collection is often not feasible.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food loss and waste reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1667Ruey Leng Loo2022-07-18T12:21:07Z<p>FitriAmalia: /* Question 3 */</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Ruey Leng Loo completed a PhD in metabolic phenotyping at the Imperial College, London. After that, she was appointed as a Lecturer and was subsequently promoted to Senior Lecturer in 2017. She moved to Murdoch University in 2019 having secured a Western Australia Premier’s Science Mid-Career Fellowship.<br />
<br />
Ruey Leng’s research focuses on biomarkers discovery in cardiovascular disease (CVD), and because the major contributing risk factors of CVD are largely affected by modifiable risk factors such as poor diet, she has also expanded her research interest to interrogate foods/food products that we eat and assess how foods affect human health a molecular level.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started using metabolomics during my PhD study in 2004 at the Imperial College London. The project applied NMR- based metabolomics to better understand the influence of diets on blood pressure. Prior to my PhD, I had no experience in metabolomics but my background in pharmacy and interest in gaining a better understanding on why people respond differently to diets and medications pique my interest in the field.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
My primary research focus remains on applying the metabolome-wide association approach to investigate cardiovascular disease risk using both population and clinical intervention studies. Since moving to the Australian National Phenome Centre (ANPC), Murdoch University in 2019, I have further expanded my research focus to include the analysis of food. I deeply characterise food compositions by leveraging the multiple analytical platforms available at the ANPC to understand the molecular basis of healthy nutrition, and ultimately connect nutritional quality and composition with positive healthcare outcomes through nutritional health claims. My research goal, therefore, aims to enable future preventative medicine strategies at the individual and population levels.<br />
<br />
===Question 3===<br />
<br />
''' 3. You contributed to the development of the metabolome-wide association study (MWAS) approaches to molecular phenotyping, what are the biggest challenges in this field and how did you overcome that? '''<br />
<br />
At the time, it was the first time metabolomics was used to analyse thousands of samples from a cross-sectional population study. The challenge is to identify a suitable data analysis strategy to unpick the subtle changes in the metabolic phenotypes and to understand the biological meaning behind these changes (and of course including the identification of the unknown metabolites). I was lucky to have good mentors so I was able to discuss these challenges with them and address them methodically.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food loss and waste reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1666Ruey Leng Loo2022-07-18T12:20:16Z<p>FitriAmalia: /* Question 2 */</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Ruey Leng Loo completed a PhD in metabolic phenotyping at the Imperial College, London. After that, she was appointed as a Lecturer and was subsequently promoted to Senior Lecturer in 2017. She moved to Murdoch University in 2019 having secured a Western Australia Premier’s Science Mid-Career Fellowship.<br />
<br />
Ruey Leng’s research focuses on biomarkers discovery in cardiovascular disease (CVD), and because the major contributing risk factors of CVD are largely affected by modifiable risk factors such as poor diet, she has also expanded her research interest to interrogate foods/food products that we eat and assess how foods affect human health a molecular level.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started using metabolomics during my PhD study in 2004 at the Imperial College London. The project applied NMR- based metabolomics to better understand the influence of diets on blood pressure. Prior to my PhD, I had no experience in metabolomics but my background in pharmacy and interest in gaining a better understanding on why people respond differently to diets and medications pique my interest in the field.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
My primary research focus remains on applying the metabolome-wide association approach to investigate cardiovascular disease risk using both population and clinical intervention studies. Since moving to the Australian National Phenome Centre (ANPC), Murdoch University in 2019, I have further expanded my research focus to include the analysis of food. I deeply characterise food compositions by leveraging the multiple analytical platforms available at the ANPC to understand the molecular basis of healthy nutrition, and ultimately connect nutritional quality and composition with positive healthcare outcomes through nutritional health claims. My research goal, therefore, aims to enable future preventative medicine strategies at the individual and population levels.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, “It is better to be rough fast than to elaborate slowly". Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food loss and waste reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1665Ruey Leng Loo2022-07-18T12:19:49Z<p>FitriAmalia: /* Question 1 */</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Ruey Leng Loo completed a PhD in metabolic phenotyping at the Imperial College, London. After that, she was appointed as a Lecturer and was subsequently promoted to Senior Lecturer in 2017. She moved to Murdoch University in 2019 having secured a Western Australia Premier’s Science Mid-Career Fellowship.<br />
<br />
Ruey Leng’s research focuses on biomarkers discovery in cardiovascular disease (CVD), and because the major contributing risk factors of CVD are largely affected by modifiable risk factors such as poor diet, she has also expanded her research interest to interrogate foods/food products that we eat and assess how foods affect human health a molecular level.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started using metabolomics during my PhD study in 2004 at the Imperial College London. The project applied NMR- based metabolomics to better understand the influence of diets on blood pressure. Prior to my PhD, I had no experience in metabolomics but my background in pharmacy and interest in gaining a better understanding on why people respond differently to diets and medications pique my interest in the field.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, “It is better to be rough fast than to elaborate slowly". Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food loss and waste reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1664Ruey Leng Loo2022-07-18T12:19:18Z<p>FitriAmalia: /* Short Biography */</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Ruey Leng Loo completed a PhD in metabolic phenotyping at the Imperial College, London. After that, she was appointed as a Lecturer and was subsequently promoted to Senior Lecturer in 2017. She moved to Murdoch University in 2019 having secured a Western Australia Premier’s Science Mid-Career Fellowship.<br />
<br />
Ruey Leng’s research focuses on biomarkers discovery in cardiovascular disease (CVD), and because the major contributing risk factors of CVD are largely affected by modifiable risk factors such as poor diet, she has also expanded her research interest to interrogate foods/food products that we eat and assess how foods affect human health a molecular level.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, “It is better to be rough fast than to elaborate slowly". Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food loss and waste reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Ruey_Leng_Loo&diff=1663Ruey Leng Loo2022-07-18T11:58:42Z<p>FitriAmalia: Created page with " Dr. Ruey Leng Loo ==Short Biography== ''' Biography''' Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving mast..."</p>
<hr />
<div>[[Image: RueyLengLoo.jpg|thumb| Dr. Ruey Leng Loo ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, “It is better to be rough fast than to elaborate slowly". Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food loss and waste reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Expert_Opinion&diff=1662Expert Opinion2022-07-18T11:57:38Z<p>FitriAmalia: </p>
<hr />
<div>The '''Expert Opinion''' is an initiative from the [[Early-Career Members Network|Early-Career Members Network (EMN) Committee]] that intends to publish career feedback from leading researchers in the metabolomics field. With that, early career researchers can get to know different specialists on the field and, more importantly, get insights and tips on how to build their on career.<br />
<br />
[[Image: RueyLengLoo.jpg|75px|link= Ruey Leng Loo]] [[Ruey Leng Loo| Dr. Ruey Leng Loo (July, 2022)]]<br />
<br />
[[Image: EiichiroFukusaki.jpg|75px|link= Eiichiro Fukusaki]] [[Eiichiro Fukusaki| Prof. Eiichiro Fukusaki (May, 2022)]]<br />
<br />
[[Image: LukeWhiley.jpg|75px|link= Luke Whiley]] [[Luke Whiley| Dr. Luke Whiley (April, 2022)]]<br />
<br />
[[Image: ShuichiShimma.jpg|75px|link= Shuichi Shimma]] [[Shuichi Shimma| Dr. Shuichi Shimma (March, 2022)]]<br />
<br />
[[Image: JohannesRainer.jpeg|75px|link= Johannes Rainer]] [[Johannes Rainer| Dr. Johannes Rainer (February, 2022)]]<br />
<br />
[[Image: TimEbbels.jpg|75px|link= Tim Ebbels]] [[Tim Ebbels| Dr. Tim Ebbels (January, 2022)]]<br />
<br />
[[Image: Michael Witting.jpg|75px|link= Michael Witting]] [[Michael Witting| Dr. Michael Witting (October, 2021)]]<br />
<br />
[[Image: Candice Ulmer.jpg|75px|link= Candice Ulmer]] [[Candice Ulmer| Dr. Candice Z. Ulmer (August, 2021)]]<br />
<br />
[[Image: Kati_Hanhineva2.jpg|75px|link= Kati Hanhineva]] [[Kati Hanhineva| Dr. Kati Hanhineva (May, 2021)]]<br />
<br />
[[Image: Justine_Bertrand-Michel.jpg|75px|link= Justine Bertrand-Michel]] [[Justine Bertrand-Michel|Dr. Justine Bertrand-Michel (April, 2021)]]<br />
<br />
[[Image:Pieter_Dorrestein.jpg|75px|link= Pieter Dorrestein]] [[Pieter Dorrestein|Professor Pieter Dorrestein (March, 2021)]]<br />
<br />
[[Image:Roy_Goodacre.png|75px|link= Roy Goodacre]] [[Roy Goodacre|Professor Roy Goodacre (February, 2021)]]<br />
<br />
[[Image: Kazuki_Saito.jpg|75px|link= Kazuki Saito]] [[Kazuki Saito|Dr. Kazuki Saito (January, 2021)]]<br />
<br />
[[Image: Augustin_Scalbert.jpg|75px|link= Augustin Scalbert]] [[Augustin Scalbert|Dr. Augustin Scalbert (December, 2020)]]<br />
<br />
[[Image: Jessica_LaskySu.jpg|75px|link= Jessica Lasky-Su]] [[Jessica Lasky-Su|Associate Professor Jessica Lasky-Su (February, 2020)]]<br />
<br />
[[Image: Nichole_Reisdorph.png|75px|link= Nichole Reisdorph]] [[Nichole Reisdorph|Dr Nichole Reisdorph (September, 2019)]]<br />
<br />
[[Image:RickDunn.png|75px|link= Rick Dunn]] [[Rick Dunn|Professor Warwick (Rick) Dunn (July, 2019)]]<br />
<br />
[[Image:Mark_R_Viant.png|75px|link= Mark Viant]] [[Mark Viant|Professor Mark Viant (April, 2019)]]<br />
<br />
[[Image:StaceyReinke.jpg|75px|link= Stacey Reinke]] [[Stacey Reinke|Dr Stacey Reinke (March, 2019)]]<br />
<br />
[[Image:Antonio.jpg|75px|link= Carla Antonio]] [[Carla_Antonio|Dr Carla Antonio (July, 2018)]]<br />
<br />
[[Image:Vanderhooft.jpg|75px|link= Justin van der Hooft]] [[Justin_van_der_Hooft|Dr Justin J.J. van der Hooft (February, 2018)]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=File:RueyLengLoo.jpg&diff=1661File:RueyLengLoo.jpg2022-07-18T11:56:34Z<p>FitriAmalia: </p>
<hr />
<div></div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Eiichiro_Fukusaki&diff=1660Eiichiro Fukusaki2022-05-17T07:57:36Z<p>FitriAmalia: /* Question 4 */</p>
<hr />
<div>[[Image: EiichiroFukusaki.jpg|thumb| Prof. Eiichiro Fukusaki ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, “It is better to be rough fast than to elaborate slowly". Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food loss and waste reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Eiichiro_Fukusaki&diff=1659Eiichiro Fukusaki2022-05-16T07:27:11Z<p>FitriAmalia: /* Question 5 */</p>
<hr />
<div>[[Image: EiichiroFukusaki.jpg|thumb| Prof. Eiichiro Fukusaki ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, “It is better to be rough fast than to elaborate slowly". Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food loss and waste reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Eiichiro_Fukusaki&diff=1658Eiichiro Fukusaki2022-05-16T07:26:13Z<p>FitriAmalia: /* Question 3 */</p>
<hr />
<div>[[Image: EiichiroFukusaki.jpg|thumb| Prof. Eiichiro Fukusaki ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, “It is better to be rough fast than to elaborate slowly". Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food and wase reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Main_Page&diff=1657Main Page2022-05-16T07:23:47Z<p>FitriAmalia: </p>
<hr />
<div>__NOTOC____NOEDITSECTION__{{notitle}}<div style="position: relative; top: -30px; z-index: 100; font-size:100%;"><br />
{|cellpadding="5" cellspacing="0"|<br />
<br />
|style="border: 1px solid #DDDDDD;font-size:120%"|<br />
Welcome to the '''Early-Career Members Network (EMN) Webpage''', a resource curated by [[Early-Career_Members_Network | Early-Career Members Network of the Metabolomics Society]]. This wiki-styled page is designed to be a focal point for educational resources and online tools related to all facets of metabolomics, aiming to reach mainly young researchers of the field.<br />
<br />
<!-- NOTES FOR THE CATEGORIES TABLE:<br />
<br />
* There is *NO* paragraph break after the <br /> tags, only a single space.<br />
* Do not enter empty lines anywhere between <span...> and </center> (breaks the formatting).<br />
* Images are taken from http://en.wikipedia.org/wiki/Wikipedia:Categorical_index<br />
<br />
<br />
--><br />
<span id="Highlights"></span><br />
<center><br />
<br />
{| width=90% style="border: 2px solid #DDDDDD; background-color:rgb(250,250,255); margin-top:10px" cellspacing=20<br />
!colspan=2 style="text-align:center; font-size:100%;"|'''Highlights'''<br />
|-<br />
!colspan=2 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;padding-left:1em;"|<br />
<h3><br />
[[Image: EiichiroFukusaki.jpg|x140px|border|link= Eiichiro Fukusaki]]<br /><br /> <br />
This month Expert Opinion comes from Prof. [[Eiichiro Fukusaki| Eiichiro Fukusaki!]]<br /><br /><br />
</h3><br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;"|<br />
<h3><br />
[[Image:Conference_2022.png|x150px|border|link=Upcoming Events]]<br /><br /> <br />
Do not miss the Metabolomics Conference 2022. Click [https://www.metabolomics2022.org/ here] to know more! <br /><br /><br />
|}<br />
<br />
<span id="Regions"></span><br />
<br />
{|width=80% style="border: 2px solid #DDDDDD; margin-top:1px" cellspacing=1;"<br />
!colspan=6 style="text-align:center; font-size:100%;"|'''Finding Metabolomics Communities'''<br />
|-<br />
!colspan=6 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:16,66%; font-size:95%; vertical-align:bottom; text-align:center;"|<br />
[[Image:128px-Blank Map-Africa.svg.png|link= Metabolomics Communities#Africa|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Africa|'''Africa''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-Location Map Asia.svg.png|link= Metabolomics Communities#Asia|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Asia|'''Asia''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:BlankMap-Europe-v4.png|link= Metabolomics Communities#Europe|x100px]]<br /><br /><br />
[[Metabolomics_Communities#Europe|'''Europe''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-America_Blank.svg.png|link=Metabolomics Communities#North and Central America|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#North and Central America|'''North & Central America''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:Blank Map Oceania3.svg.png|link=Metabolomics Communities#Oceania|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Oceania|'''Oceania''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-BlankMap-South-America.png|link= Communities#South America|x100px]]<br /><br /><br />
[[Metabolomics_Communities#South America|'''South America''']] <br /><br /> <br />
|}<br />
<br />
<span id="Keep updated! Follow us"></span><br />
{| width=90% style="border: 2px solid #DDDDDD; ; margin-top:20px" cellspacing=6<br />
!colspan=3 style="text-align:center; font-size:100%;"|'''Keep updated! Follow us on social medias!'''<br />
|-<br />
!colspan=3 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:right; padding-left:1em;"|<br />
[[Image: Facebook.png|70px|link=https://www.facebook.com/EMN.MetabolomicsSociety]]<br /><br /> <br />
|style="width:20%; font-size:95%; vertical-align:center; text-align:left;"|<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:left;"|<br />
[[Image:Twitter.png|70px|link=https://twitter.com/emn_metsoc?lang=pt]]<br /><br /> <br />
</h3><br />
|}<br />
If you would like to suggest content, please contact the current EMN committee at ''info.emn@metabolomicssociety.org''<br />
|}</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Main_Page&diff=1656Main Page2022-05-16T07:23:33Z<p>FitriAmalia: </p>
<hr />
<div>__NOTOC____NOEDITSECTION__{{notitle}}<div style="position: relative; top: -30px; z-index: 100; font-size:100%;"><br />
{|cellpadding="5" cellspacing="0"|<br />
<br />
|style="border: 1px solid #DDDDDD;font-size:120%"|<br />
Welcome to the '''Early-Career Members Network (EMN) Webpage''', a resource curated by [[Early-Career_Members_Network | Early-Career Members Network of the Metabolomics Society]]. This wiki-styled page is designed to be a focal point for educational resources and online tools related to all facets of metabolomics, aiming to reach mainly young researchers of the field.<br />
<br />
<!-- NOTES FOR THE CATEGORIES TABLE:<br />
<br />
* There is *NO* paragraph break after the <br /> tags, only a single space.<br />
* Do not enter empty lines anywhere between <span...> and </center> (breaks the formatting).<br />
* Images are taken from http://en.wikipedia.org/wiki/Wikipedia:Categorical_index<br />
<br />
<br />
--><br />
<span id="Highlights"></span><br />
<center><br />
<br />
{| width=90% style="border: 2px solid #DDDDDD; background-color:rgb(250,250,255); margin-top:10px" cellspacing=20<br />
!colspan=2 style="text-align:center; font-size:100%;"|'''Highlights'''<br />
|-<br />
!colspan=2 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;padding-left:1em;"|<br />
<h3><br />
[[Image: EiichiroFukusaki.jpg|x140px|border|link= Eiichiro Fukusaki]]<br /><br /> <br />
This month Expert Opinion comes from Prof. [[Eiichiro Fukusaki| Prof. Eiichiro Fukusaki!]]<br /><br /><br />
</h3><br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;"|<br />
<h3><br />
[[Image:Conference_2022.png|x150px|border|link=Upcoming Events]]<br /><br /> <br />
Do not miss the Metabolomics Conference 2022. Click [https://www.metabolomics2022.org/ here] to know more! <br /><br /><br />
|}<br />
<br />
<span id="Regions"></span><br />
<br />
{|width=80% style="border: 2px solid #DDDDDD; margin-top:1px" cellspacing=1;"<br />
!colspan=6 style="text-align:center; font-size:100%;"|'''Finding Metabolomics Communities'''<br />
|-<br />
!colspan=6 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:16,66%; font-size:95%; vertical-align:bottom; text-align:center;"|<br />
[[Image:128px-Blank Map-Africa.svg.png|link= Metabolomics Communities#Africa|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Africa|'''Africa''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-Location Map Asia.svg.png|link= Metabolomics Communities#Asia|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Asia|'''Asia''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:BlankMap-Europe-v4.png|link= Metabolomics Communities#Europe|x100px]]<br /><br /><br />
[[Metabolomics_Communities#Europe|'''Europe''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-America_Blank.svg.png|link=Metabolomics Communities#North and Central America|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#North and Central America|'''North & Central America''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:Blank Map Oceania3.svg.png|link=Metabolomics Communities#Oceania|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Oceania|'''Oceania''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-BlankMap-South-America.png|link= Communities#South America|x100px]]<br /><br /><br />
[[Metabolomics_Communities#South America|'''South America''']] <br /><br /> <br />
|}<br />
<br />
<span id="Keep updated! Follow us"></span><br />
{| width=90% style="border: 2px solid #DDDDDD; ; margin-top:20px" cellspacing=6<br />
!colspan=3 style="text-align:center; font-size:100%;"|'''Keep updated! Follow us on social medias!'''<br />
|-<br />
!colspan=3 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:right; padding-left:1em;"|<br />
[[Image: Facebook.png|70px|link=https://www.facebook.com/EMN.MetabolomicsSociety]]<br /><br /> <br />
|style="width:20%; font-size:95%; vertical-align:center; text-align:left;"|<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:left;"|<br />
[[Image:Twitter.png|70px|link=https://twitter.com/emn_metsoc?lang=pt]]<br /><br /> <br />
</h3><br />
|}<br />
If you would like to suggest content, please contact the current EMN committee at ''info.emn@metabolomicssociety.org''<br />
|}</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Eiichiro_Fukusaki&diff=1655Eiichiro Fukusaki2022-05-16T07:22:25Z<p>FitriAmalia: /* Question 6 */</p>
<hr />
<div>[[Image: EiichiroFukusaki.jpg|thumb| Prof. Eiichiro Fukusaki ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, ’Fast but slow’ is better than ‘skillful but slow’. Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food and wase reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important to research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Eiichiro_Fukusaki&diff=1654Eiichiro Fukusaki2022-05-16T07:21:49Z<p>FitriAmalia: /* Question 5 */</p>
<hr />
<div>[[Image: EiichiroFukusaki.jpg|thumb| Prof. Eiichiro Fukusaki ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, ’Fast but slow’ is better than ‘skillful but slow’. Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food and wase reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials". In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption". The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs". Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Eiichiro_Fukusaki&diff=1653Eiichiro Fukusaki2022-05-16T07:20:37Z<p>FitriAmalia: /* Question 3 */</p>
<hr />
<div>[[Image: EiichiroFukusaki.jpg|thumb| Prof. Eiichiro Fukusaki ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, ’Fast but slow’ is better than ‘skillful but slow’. Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food and wase reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials" . In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption" . The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs. " Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Eiichiro_Fukusaki&diff=1652Eiichiro Fukusaki2022-05-16T07:20:13Z<p>FitriAmalia: /* Question 3 */</p>
<hr />
<div>[[Image: EiichiroFukusaki.jpg|thumb| Prof. Eiichiro Fukusaki ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, ’Fast but slow’ is better than ‘skillful but slow’. Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food and wase reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials" . In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption" . The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs. " Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Eiichiro_Fukusaki&diff=1651Eiichiro Fukusaki2022-05-16T07:19:39Z<p>FitriAmalia: </p>
<hr />
<div>[[Image: EiichiroFukusaki.jpg|thumb| Prof. Eiichiro Fukusaki ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
After graduating from Osaka university, I was engaged in research on large scale practical synthetic processes of bioactive substances in a private company. <br />
After 10 years company experience, I received an offer from Osaka University to become an associate professor in 1995. My new boss at Osaka University was a specialist in analytical chemistry and natural product organic chemistry. <br />
He strongly required me to do the two things.<br />
One was not to continue the synthetic chemistry research I had been doing at the company, but to start something completely new from scratch. The second was that the new research should be centered on analytical chemistry.<br />
Therefore, I decided to focus on biosynthesis, which is an organic synthetic reaction in living organisms, and to develop new technologies for the comprehensive analysis of organic compounds, which are biosynthetic products, as my new research subject. After much trial and error, I decided to focus on metabolomics research, which is what I am doing now, from around 2000.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Since 2000, I have been conducting technology-driven application research in various fields using GC/MS, LC/MS, and NMR. In order to maintain good relationships with prestigious collaborative clients, I have avoided having our own research samples as much as possible. As a result, my research targets have been extremely wide-ranging, including basic biology, medicine, drug discovery, microbiology, fermentation production, and food. However, based on the idea that selection and concentration are necessary to become a first-rate researcher, I gradually narrowed down my research targets to food and fermentation. Recently, I have concentrated especially on applications based on comprehensive analysis of volatile metabolites in foods.<br />
<br />
===Question 3===<br />
<br />
''' 3. During your career you have worked in both industry and academia; what are the main differences working in these environments? What are the skills gained through your experience in the industry that benefits the academic process? '''<br />
<br />
There may be exceptions, but the basic difference is that corporate research is technological development for the pursuit of profit, while research in academia is aimed at the search for truth and the training of future generations. Corporate research always prioritizes speed while considering the 3C's (Company, Customer, Competitor). The most important thing I learned in the corporate world is the "sense of speed". The ancients said, ’Fast but slow’ is better than ‘skillful but slow’. Even now, I conduct my research and education based on the principle.<br />
<br />
===Question 4===<br />
<br />
''' 4. Since you are an expert in food metabolomics method development and application, are there any challenges applying metabolomics in food samples? How did you overcome this challenge? '''<br />
<br />
First, I had a hard time maintaining the freshness of food samples. I often worked with perishable foods such as fruits and seafood from overseas, and I had great difficulty in finding ways to import food samples from overseas with minimal deterioration. To solve this problem, I spent a lot of time optimizing sampling, storage, and logistic methods. Needless to say, I was supported by the dedication of our international collaborators. Another important aspect of food metabolomics is the food-derived response variable, which is necessary to construct regression prediction models using metabolomes as explanatory variables. Especially in the case of secondary functions of foods, I had a great deal of difficulty in obtaining reproducible sensory evaluation data. At first, I depended on my collaborators who provided food samples for sensory evaluation, but recently, I have started to conduct sensory evaluation of various foods in my own laboratory.<br />
<br />
===Question 5===<br />
<br />
''' 5. We are interested in one of your recent projects about contributing to the United Nations' Sustainable Development Goals (UN-SDG) (https://handaifoodloss.otri.osaka-u.ac.jp/), Could you explain in detail how metabolomics could contribute to this matter? '''<br />
<br />
As you mentioned, I started the "Food and wase reduction innovation Hub" project with the support of JST last fiscal year. This project is a collaborative effort to develop new technologies such as "development of rapid monitoring technology for food functions" , "development of smart data logger system" and "development and utilization of zero-waste recycling food materials" . In addition to the challenges of developing new technologies, the project is also involved in social science research projects such as "Building a sustainable socio-economics system through ethical consumption" . The project is a large-scale fusion of the humanities and sciences, including research projects such as "Developing human resources for food solutions and creating opportunities through interactive international education programs. " Food metabolomics technology targeting volatile metabolites is positioned as an important core competence technology in this project.<br />
<br />
===Question 6===<br />
<br />
''' 6. Do you have any advice for early career researchers that interested to be involved in food metabolomics? '''<br />
<br />
As I mentioned earlier, for successful food metabolomics, in addition to metabolomics techniques, "sample freshness maintenance techniques" and "procurement of useful response variables for social demand" are important. To achieve these goals, I think it is necessary to be constantly aware of global needs and to make diplomatic efforts to obtain the best collaborative research partners. Food research is more difficult to obtain research funds than medical research, but it is important research that is indispensable for the future of the world. I hope that more young people will enter food metabolomics research.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Eiichiro_Fukusaki&diff=1650Eiichiro Fukusaki2022-05-16T07:14:53Z<p>FitriAmalia: Created page with " Prof. Eiichiro Fukusaki ==Short Biography== ''' Biography''' Eiichiro Fukusaki entered a private company, Nitto Denko Co, after rec..."</p>
<hr />
<div>[[Image: EiichiroFukusaki.jpg|thumb| Prof. Eiichiro Fukusaki ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Eiichiro Fukusaki entered a private company, Nitto Denko Co, after receiving master degree from Osaka University on 1985. He received PhD from Osaka University on 1993 through his company work.<br />
After ten years company experience, he returned back to Osaka University as an associate professor. On 2007 he has been assigned as a full professor in department of biotechnology, graduate school of engineering, Osaka University.<br />
He received several awards including; an Excellent Paper Award of the Society for Biotechnology, Japan [1993, 2003, 2007, 2009, 2012, 2015], the Japanese Society for Chemical Regulation of Plants Award for the Encouragement of Young Scientists. [2001]; the Society of Biotechnology, Japan ‘Saito’ Award [2004]; the Society of Biotechnology, Japan Achievement Award [2015]; Excellent Paper Award of Division of Chemical Information and Computer Science, The Chemical Society of Japan [2009]. He was assigned as a life-time honorary fellow of Metabolomics International Society [2019]. His current research interests are focusing on development and application of metabolomics technology. He has published over 300 original papers and 50 patents. He is focusing on not only fundamental science but also practical application. Particularly he facilitates research collaboration with private companies in the several fields including food, chemical, pharmaceutical, analytical etc. He is also energetically promoting international education and research collaboration. Recently he has participated double degree program in graduated school level between Osaka University and several foreign universities.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started down the path of metabolomics during my PhD research in 2009. My research aim was to identify blood-based biomarkers of Alzheimer’s disease. Before my PhD, I had already had some experience in analytical chemistry and small molecule LC-MS, and the PhD project had access to an LC-QToF-MS, so it was a natural fit that kicked off a metabolomics and lipidomics journey!<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
I’m currently based in Australia. I moved over from the UK in 2019 to help set up the Australian National Phenome Centre (ANPC) in Perth. Since I have been here, I have been working on building up metabolomics mass spectrometry methods and creating new collaborations, both nationally and internationally, as the centre goes through its formative years. My primary research interest in metabolomics remains in the neurodegenerative space, specifically - studying the mechanism and metabolism of neurodegeneration. The aim of this research is two fold; first, can we identify early mechanistic pathways that contribute to disease; and second to build an understanding of the wider impact of neurodegeneration on systemic metabolism. A recent interesting project that highlights this is the application of mass spectrometry metabolomics to serum collected from models of traumatic brain injury, with the aim to identify possible blood-based prognosis predictors of injury.<br />
<br />
===Question 3===<br />
<br />
''' 3. You are actively involved in neurodegenerative disease-related research, such as Alzheimer's and dementia. What are the advantages of involving metabolomics in this field? '''<br />
<br />
Our knowledge of Alzheimer’s disease is rapidly advancing all the time, but there are still some major gaps – particularly in our understanding of those who are most at risk of developing the disease and why they develop it. Although we now are adept at identifying genetic risk factors, how those risk factors translate to disease incidence and detailing the mechanisms that underpin them often remains unclear. Metabolomics gives us the opportunity to investigate this from a metabolic pathway and mechanistic viewpoint. I think over the coming years we will see much more research investigating the specific metabolic mechanisms of genetic and environmental risk of disease. This will really help us build the specific pathways that influence disease and the subsequent mechanistic picture as to why certain individuals go on to develop the disease and then perhaps we can then modify these pathways, and delay the progression of disease.<br />
<br />
===Question 4===<br />
<br />
''' 4. You often use urine or serum as the samples for untargeted metabolomics studies for phenotyping Alzheimer's and dementia diseases. What are the challenges in translating the results found using this kind of samples into a more local understanding of the nervous system once samples like CSF and brain tissue are very unavailable? '''<br />
<br />
This is certainly a huge challenge in the field – and something that is really interesting to consider when performing such research. Typically, such analysis reveals systemic changes, rather than direct metabolites of the neurodegeneration itself. The challenge to unpick these patterns that we see in the data and determine if they are in anyway causative factors in the disease or if they are a response to disease pathology itself. One such way we can attempt to address this is to work on longitudinal cohorts, and to study the metabolism of “healthy” populations, before they develop neurodegenerative diseases. By retrospectively looking at this data in combination with up-to-date current clinical data of the participants diagnostic outcome, we can try to observe metabolic patterns in populations that could indicate those who later go on to develop neurodegenerative conditions.<br />
<br />
===Question 5===<br />
<br />
''' 5. Would you mind sharing any interesting findings in the application of metabolomics in neurodegenerative disease? '''<br />
<br />
We collaborate with a group in Singapore who are interested in the influence of the gut microbiome on the host neurological system. We recently helped them by applying mass spectrometry metabolomics platforms to measure specific plasma metabolites. The project was able to demonstrate that these metabolites, secreted by gut-microbes, go on to influence adult neurogenesis. The data indicates that a symbiotic gut–brain coregulatory axis exists, connecting the metabolic status of gut microbes to the control of neurogenesis in the brain. The gut-brain axis is a really interesting area of research, and the concept that the microbes in our gut can influence our neurological system, mood and even regulate neurogenesis is fascinating.<br />
<br />
===Question 6===<br />
<br />
''' 6. What you would say are next hot topics in the field of neurodegenerative diseases that early career researchers in the field of metabolomics could strongly contribute to? '''<br />
<br />
I think data integration will become a hot (hotter?) topic in the field, both in terms of combining metabolomic data from cohorts from around the world to create larger datasets to combining different omic techniques, for example, metabolomics, microbiomics, genomics. To achieve this we will need early career researcher contributions in a variety of areas at every stage of the pipeline. For example – we will need analytical chemistry experts who specialise in the analytical platforms and data acquisition, as we will need robust and reproducible data that can be translated to collaborating groups. We will also need researchers who can contribute in the bioinformatics of such projects - to combine and match data from different cohorts, and then work on integrating data acquired from the different omic technologies. By achieving this we can build giant datasets, and mine them to finely detail the mechanism of systemic diseases. Also, research into the metabolism of the human microbiome will grow (more!), we’ve already touched above on the gut-brain axis, and I think that research into host-microbe interactions at a metabolic level will be hot topics going forwards, as will combining these datasets and interpreting the interactions at a metabolite level through metabolomics, and the subsequent impact and influence on disease, will be a fascinating research area.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Expert_Opinion&diff=1649Expert Opinion2022-05-16T07:12:47Z<p>FitriAmalia: </p>
<hr />
<div>The '''Expert Opinion''' is an initiative from the [[Early-Career Members Network|Early-Career Members Network (EMN) Committee]] that intends to publish career feedback from leading researchers in the metabolomics field. With that, early career researchers can get to know different specialists on the field and, more importantly, get insights and tips on how to build their on career.<br />
<br />
[[Image: EiichiroFukusaki.jpg|75px|link= Eiichiro Fukusaki]] [[Eiichiro Fukusaki| Prof. Eiichiro Fukusaki (May, 2022)]]<br />
<br />
[[Image: LukeWhiley.jpg|75px|link= Luke Whiley]] [[Luke Whiley| Dr. Luke Whiley (April, 2022)]]<br />
<br />
[[Image: ShuichiShimma.jpg|75px|link= Shuichi Shimma]] [[Shuichi Shimma| Dr. Shuichi Shimma (March, 2022)]]<br />
<br />
[[Image: JohannesRainer.jpeg|75px|link= Johannes Rainer]] [[Johannes Rainer| Dr. Johannes Rainer (February, 2022)]]<br />
<br />
[[Image: TimEbbels.jpg|75px|link= Tim Ebbels]] [[Tim Ebbels| Dr. Tim Ebbels (January, 2022)]]<br />
<br />
[[Image: Michael Witting.jpg|75px|link= Michael Witting]] [[Michael Witting| Dr. Michael Witting (October, 2021)]]<br />
<br />
[[Image: Candice Ulmer.jpg|75px|link= Candice Ulmer]] [[Candice Ulmer| Dr. Candice Z. Ulmer (August, 2021)]]<br />
<br />
[[Image: Kati_Hanhineva2.jpg|75px|link= Kati Hanhineva]] [[Kati Hanhineva| Dr. Kati Hanhineva (May, 2021)]]<br />
<br />
[[Image: Justine_Bertrand-Michel.jpg|75px|link= Justine Bertrand-Michel]] [[Justine Bertrand-Michel|Dr. Justine Bertrand-Michel (April, 2021)]]<br />
<br />
[[Image:Pieter_Dorrestein.jpg|75px|link= Pieter Dorrestein]] [[Pieter Dorrestein|Professor Pieter Dorrestein (March, 2021)]]<br />
<br />
[[Image:Roy_Goodacre.png|75px|link= Roy Goodacre]] [[Roy Goodacre|Professor Roy Goodacre (February, 2021)]]<br />
<br />
[[Image: Kazuki_Saito.jpg|75px|link= Kazuki Saito]] [[Kazuki Saito|Dr. Kazuki Saito (January, 2021)]]<br />
<br />
[[Image: Augustin_Scalbert.jpg|75px|link= Augustin Scalbert]] [[Augustin Scalbert|Dr. Augustin Scalbert (December, 2020)]]<br />
<br />
[[Image: Jessica_LaskySu.jpg|75px|link= Jessica Lasky-Su]] [[Jessica Lasky-Su|Associate Professor Jessica Lasky-Su (February, 2020)]]<br />
<br />
[[Image: Nichole_Reisdorph.png|75px|link= Nichole Reisdorph]] [[Nichole Reisdorph|Dr Nichole Reisdorph (September, 2019)]]<br />
<br />
[[Image:RickDunn.png|75px|link= Rick Dunn]] [[Rick Dunn|Professor Warwick (Rick) Dunn (July, 2019)]]<br />
<br />
[[Image:Mark_R_Viant.png|75px|link= Mark Viant]] [[Mark Viant|Professor Mark Viant (April, 2019)]]<br />
<br />
[[Image:StaceyReinke.jpg|75px|link= Stacey Reinke]] [[Stacey Reinke|Dr Stacey Reinke (March, 2019)]]<br />
<br />
[[Image:Antonio.jpg|75px|link= Carla Antonio]] [[Carla_Antonio|Dr Carla Antonio (July, 2018)]]<br />
<br />
[[Image:Vanderhooft.jpg|75px|link= Justin van der Hooft]] [[Justin_van_der_Hooft|Dr Justin J.J. van der Hooft (February, 2018)]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=File:EiichiroFukusaki.jpg&diff=1648File:EiichiroFukusaki.jpg2022-05-16T07:11:55Z<p>FitriAmalia: </p>
<hr />
<div></div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Main_Page&diff=1647Main Page2022-04-12T05:32:57Z<p>FitriAmalia: </p>
<hr />
<div>__NOTOC____NOEDITSECTION__{{notitle}}<div style="position: relative; top: -30px; z-index: 100; font-size:100%;"><br />
{|cellpadding="5" cellspacing="0"|<br />
<br />
|style="border: 1px solid #DDDDDD;font-size:120%"|<br />
Welcome to the '''Early-Career Members Network (EMN) Webpage''', a resource curated by [[Early-Career_Members_Network | Early-Career Members Network of the Metabolomics Society]]. This wiki-styled page is designed to be a focal point for educational resources and online tools related to all facets of metabolomics, aiming to reach mainly young researchers of the field.<br />
<br />
<!-- NOTES FOR THE CATEGORIES TABLE:<br />
<br />
* There is *NO* paragraph break after the <br /> tags, only a single space.<br />
* Do not enter empty lines anywhere between <span...> and </center> (breaks the formatting).<br />
* Images are taken from http://en.wikipedia.org/wiki/Wikipedia:Categorical_index<br />
<br />
<br />
--><br />
<span id="Highlights"></span><br />
<center><br />
<br />
{| width=90% style="border: 2px solid #DDDDDD; background-color:rgb(250,250,255); margin-top:10px" cellspacing=20<br />
!colspan=2 style="text-align:center; font-size:100%;"|'''Highlights'''<br />
|-<br />
!colspan=2 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;padding-left:1em;"|<br />
<h3><br />
[[Image: LukeWhiley.jpg|x140px|border|link= Luke Whiley]]<br /><br /> <br />
This month Expert Opinion comes from Dr [[Luke Whiley| Luke Whiley!]]<br /><br /><br />
</h3><br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;"|<br />
<h3><br />
[[Image:Conference_2022.png|x150px|border|link=Upcoming Events]]<br /><br /> <br />
Do not miss the Metabolomics Conference 2022. Click [https://www.metabolomics2022.org/ here] to know more! <br /><br /><br />
|}<br />
<br />
<span id="Regions"></span><br />
<br />
{|width=80% style="border: 2px solid #DDDDDD; margin-top:1px" cellspacing=1;"<br />
!colspan=6 style="text-align:center; font-size:100%;"|'''Finding Metabolomics Communities'''<br />
|-<br />
!colspan=6 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:16,66%; font-size:95%; vertical-align:bottom; text-align:center;"|<br />
[[Image:128px-Blank Map-Africa.svg.png|link= Metabolomics Communities#Africa|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Africa|'''Africa''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-Location Map Asia.svg.png|link= Metabolomics Communities#Asia|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Asia|'''Asia''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:BlankMap-Europe-v4.png|link= Metabolomics Communities#Europe|x100px]]<br /><br /><br />
[[Metabolomics_Communities#Europe|'''Europe''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-America_Blank.svg.png|link=Metabolomics Communities#North and Central America|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#North and Central America|'''North & Central America''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:Blank Map Oceania3.svg.png|link=Metabolomics Communities#Oceania|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Oceania|'''Oceania''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-BlankMap-South-America.png|link= Communities#South America|x100px]]<br /><br /><br />
[[Metabolomics_Communities#South America|'''South America''']] <br /><br /> <br />
|}<br />
<br />
<span id="Keep updated! Follow us"></span><br />
{| width=90% style="border: 2px solid #DDDDDD; ; margin-top:20px" cellspacing=6<br />
!colspan=3 style="text-align:center; font-size:100%;"|'''Keep updated! Follow us on social medias!'''<br />
|-<br />
!colspan=3 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:right; padding-left:1em;"|<br />
[[Image: Facebook.png|70px|link=https://www.facebook.com/EMN.MetabolomicsSociety]]<br /><br /> <br />
|style="width:20%; font-size:95%; vertical-align:center; text-align:left;"|<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:left;"|<br />
[[Image:Twitter.png|70px|link=https://twitter.com/emn_metsoc?lang=pt]]<br /><br /> <br />
</h3><br />
|}<br />
If you would like to suggest content, please contact the current EMN committee at ''info.emn@metabolomicssociety.org''<br />
|}</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Luke_Whiley&diff=1646Luke Whiley2022-04-12T05:31:20Z<p>FitriAmalia: </p>
<hr />
<div>[[Image: LukeWhiley.jpg|thumb| Luke Whiley (BSc, PhD) ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
I am a researcher based at Murdoch University, Perth, Australia and specialise in metabolism and phenomics applications in healthy ageing and dementia. Specifically, my research interests lie in identifying the systemic metabolism that underpins disease risk. I’m particularly interested in the complex interactions between genetics, lifestyle, and environment and how these interactions influence the chance of developing neurodegenerative conditions and dementias including Alzheimer’s disease. <br />
<br />
Previously, my research in the metabolic phenotyping has taken me to university research teams in the UK (King’s College London, Imperial College London) and Spain (Universidad CEU, Madrid) before arriving at Murdoch University in October 2019. I specialise in metabolic phenotyping and metabolomics using mass spectrometry, including both discovery and targeted workflows. I enjoy working and continued development of skills across the complete pipeline; from mass spectrometry method development, raw data acquisition, data pre-processing and multivariate and univariate statistical data analysis. In 2021 I was named one of the American Chemical Society’s Rising Stars in Metabolomics and Proteomics for my research.<br />
<br />
I am passionate in public outreach programs and the communication of research, and I have been involved with social media campaigns for dementia charities, including the Dementia Revolution London Marathon campaign, and have appeared on ABC Perth Radio, Pint of Science and multiple SciComm podcasts, including the Naked Scientist and Avid research.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started down the path of metabolomics during my PhD research in 2009. My research aim was to identify blood-based biomarkers of Alzheimer’s disease. Before my PhD, I had already had some experience in analytical chemistry and small molecule LC-MS, and the PhD project had access to an LC-QToF-MS, so it was a natural fit that kicked off a metabolomics and lipidomics journey!<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
I’m currently based in Australia. I moved over from the UK in 2019 to help set up the Australian National Phenome Centre (ANPC) in Perth. Since I have been here, I have been working on building up metabolomics mass spectrometry methods and creating new collaborations, both nationally and internationally, as the centre goes through its formative years. My primary research interest in metabolomics remains in the neurodegenerative space, specifically - studying the mechanism and metabolism of neurodegeneration. The aim of this research is two fold; first, can we identify early mechanistic pathways that contribute to disease; and second to build an understanding of the wider impact of neurodegeneration on systemic metabolism. A recent interesting project that highlights this is the application of mass spectrometry metabolomics to serum collected from models of traumatic brain injury, with the aim to identify possible blood-based prognosis predictors of injury.<br />
<br />
===Question 3===<br />
<br />
''' 3. You are actively involved in neurodegenerative disease-related research, such as Alzheimer's and dementia. What are the advantages of involving metabolomics in this field? '''<br />
<br />
Our knowledge of Alzheimer’s disease is rapidly advancing all the time, but there are still some major gaps – particularly in our understanding of those who are most at risk of developing the disease and why they develop it. Although we now are adept at identifying genetic risk factors, how those risk factors translate to disease incidence and detailing the mechanisms that underpin them often remains unclear. Metabolomics gives us the opportunity to investigate this from a metabolic pathway and mechanistic viewpoint. I think over the coming years we will see much more research investigating the specific metabolic mechanisms of genetic and environmental risk of disease. This will really help us build the specific pathways that influence disease and the subsequent mechanistic picture as to why certain individuals go on to develop the disease and then perhaps we can then modify these pathways, and delay the progression of disease.<br />
<br />
===Question 4===<br />
<br />
''' 4. You often use urine or serum as the samples for untargeted metabolomics studies for phenotyping Alzheimer's and dementia diseases. What are the challenges in translating the results found using this kind of samples into a more local understanding of the nervous system once samples like CSF and brain tissue are very unavailable? '''<br />
<br />
This is certainly a huge challenge in the field – and something that is really interesting to consider when performing such research. Typically, such analysis reveals systemic changes, rather than direct metabolites of the neurodegeneration itself. The challenge to unpick these patterns that we see in the data and determine if they are in anyway causative factors in the disease or if they are a response to disease pathology itself. One such way we can attempt to address this is to work on longitudinal cohorts, and to study the metabolism of “healthy” populations, before they develop neurodegenerative diseases. By retrospectively looking at this data in combination with up-to-date current clinical data of the participants diagnostic outcome, we can try to observe metabolic patterns in populations that could indicate those who later go on to develop neurodegenerative conditions.<br />
<br />
===Question 5===<br />
<br />
''' 5. Would you mind sharing any interesting findings in the application of metabolomics in neurodegenerative disease? '''<br />
<br />
We collaborate with a group in Singapore who are interested in the influence of the gut microbiome on the host neurological system. We recently helped them by applying mass spectrometry metabolomics platforms to measure specific plasma metabolites. The project was able to demonstrate that these metabolites, secreted by gut-microbes, go on to influence adult neurogenesis. The data indicates that a symbiotic gut–brain coregulatory axis exists, connecting the metabolic status of gut microbes to the control of neurogenesis in the brain. The gut-brain axis is a really interesting area of research, and the concept that the microbes in our gut can influence our neurological system, mood and even regulate neurogenesis is fascinating.<br />
<br />
===Question 6===<br />
<br />
''' 6. What you would say are next hot topics in the field of neurodegenerative diseases that early career researchers in the field of metabolomics could strongly contribute to? '''<br />
<br />
I think data integration will become a hot (hotter?) topic in the field, both in terms of combining metabolomic data from cohorts from around the world to create larger datasets to combining different omic techniques, for example, metabolomics, microbiomics, genomics. To achieve this we will need early career researcher contributions in a variety of areas at every stage of the pipeline. For example – we will need analytical chemistry experts who specialise in the analytical platforms and data acquisition, as we will need robust and reproducible data that can be translated to collaborating groups. We will also need researchers who can contribute in the bioinformatics of such projects - to combine and match data from different cohorts, and then work on integrating data acquired from the different omic technologies. By achieving this we can build giant datasets, and mine them to finely detail the mechanism of systemic diseases. Also, research into the metabolism of the human microbiome will grow (more!), we’ve already touched above on the gut-brain axis, and I think that research into host-microbe interactions at a metabolic level will be hot topics going forwards, as will combining these datasets and interpreting the interactions at a metabolite level through metabolomics, and the subsequent impact and influence on disease, will be a fascinating research area.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Luke_Whiley&diff=1645Luke Whiley2022-04-12T05:29:41Z<p>FitriAmalia: </p>
<hr />
<div>[[Image: LukeWhiley.jpg|thumb| Luke Whiley (BSc, PhD) ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
I am a researcher based at Murdoch University, Perth, Australia and specialise in metabolism and phenomics applications in healthy ageing and dementia. Specifically, my research interests lie in identifying the systemic metabolism that underpins disease risk. I’m particularly interested in the complex interactions between genetics, lifestyle, and environment and how these interactions influence the chance of developing neurodegenerative conditions and dementias including Alzheimer’s disease. <br />
<br />
Previously, my research in the metabolic phenotyping has taken me to university research teams in the UK (King’s College London, Imperial College London) and Spain (Universidad CEU, Madrid) before arriving at Murdoch University in October 2019. I specialise in metabolic phenotyping and metabolomics using mass spectrometry, including both discovery and targeted workflows. I enjoy working and continued development of skills across the complete pipeline; from mass spectrometry method development, raw data acquisition, data pre-processing and multivariate and univariate statistical data analysis. In 2021 I was named one of the American Chemical Society’s Rising Stars in Metabolomics and Proteomics for my research.<br />
<br />
I am passionate in public outreach programs and the communication of research, and I have been involved with social media campaigns for dementia charities, including the Dementia Revolution London Marathon campaign, and have appeared on ABC Perth Radio, Pint of Science and multiple SciComm podcasts, including the Naked Scientist and Avid research.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started down the path of metabolomics during my PhD research in 2009. My research aim was to identify blood-based biomarkers of Alzheimer’s disease. Before my PhD, I had already had some experience in analytical chemistry and small molecule LC-MS, and the PhD project had access to an LC-QToF-MS, so it was a natural fit that kicked off a metabolomics and lipidomics journey!<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
I’m currently based in Australia. I moved over from the UK in 2019 to help set up the Australian National Phenome Centre (ANPC) in Perth. Since I have been here, I have been working on building up metabolomics mass spectrometry methods and creating new collaborations, both nationally and internationally, as the centre goes through its formative years. <br />
<br />
My primary research interest in metabolomics remains in the neurodegenerative space, specifically - studying the mechanism and metabolism of neurodegeneration. The aim of this research is two fold; first, can we identify early mechanistic pathways that contribute to disease; and second to build an understanding of the wider impact of neurodegeneration on systemic metabolism. <br />
<br />
A recent interesting project that highlights this is the application of mass spectrometry metabolomics to serum collected from models of traumatic brain injury, with the aim to identify possible blood-based prognosis predictors of injury.<br />
<br />
===Question 3===<br />
<br />
''' 3. You are actively involved in neurodegenerative disease-related research, such as Alzheimer's and dementia. What are the advantages of involving metabolomics in this field? '''<br />
<br />
Our knowledge of Alzheimer’s disease is rapidly advancing all the time, but there are still some major gaps – particularly in our understanding of those who are most at risk of developing the disease and why they develop it. Although we now are adept at identifying genetic risk factors, how those risk factors translate to disease incidence and detailing the mechanisms that underpin them often remains unclear. <br />
<br />
Metabolomics gives us the opportunity to investigate this from a metabolic pathway and mechanistic viewpoint. I think over the coming years we will see much more research investigating the specific metabolic mechanisms of genetic and environmental risk of disease. This will really help us build the specific pathways that influence disease and the subsequent mechanistic picture as to why certain individuals go on to develop the disease and then perhaps we can then modify these pathways, and delay the progression of disease.<br />
<br />
===Question 4===<br />
<br />
''' 4. You often use urine or serum as the samples for untargeted metabolomics studies for phenotyping Alzheimer's and dementia diseases. What are the challenges in translating the results found using this kind of samples into a more local understanding of the nervous system once samples like CSF and brain tissue are very unavailable? '''<br />
<br />
This is certainly a huge challenge in the field – and something that is really interesting to consider when performing such research. Typically, such analysis reveals systemic changes, rather than direct metabolites of the neurodegeneration itself. The challenge to unpick these patterns that we see in the data and determine if they are in anyway causative factors in the disease or if they are a response to disease pathology itself. <br />
<br />
One such way we can attempt to address this is to work on longitudinal cohorts, and to study the metabolism of “healthy” populations, before they develop neurodegenerative diseases. By retrospectively looking at this data in combination with up-to-date current clinical data of the participants diagnostic outcome, we can try to observe metabolic patterns in populations that could indicate those who later go on to develop neurodegenerative conditions.<br />
<br />
===Question 5===<br />
<br />
''' 5. Would you mind sharing any interesting findings in the application of metabolomics in neurodegenerative disease? '''<br />
<br />
We collaborate with a group in Singapore who are interested in the influence of the gut microbiome on the host neurological system. We recently helped them by applying mass spectrometry metabolomics platforms to measure specific plasma metabolites. The project was able to demonstrate that these metabolites, secreted by gut-microbes, go on to influence adult neurogenesis. The data indicates that a symbiotic gut–brain coregulatory axis exists, connecting the metabolic status of gut microbes to the control of neurogenesis in the brain. <br />
<br />
The gut-brain axis is a really interesting area of research, and the concept that the microbes in our gut can influence our neurological system, mood and even regulate neurogenesis is fascinating.<br />
<br />
===Question 6===<br />
<br />
''' 6. What you would say are next hot topics in the field of neurodegenerative diseases that early career researchers in the field of metabolomics could strongly contribute to? '''<br />
<br />
I think data integration will become a hot (hotter?) topic in the field, both in terms of combining metabolomic data from cohorts from around the world to create larger datasets to combining different omic techniques, for example, metabolomics, microbiomics, genomics. <br />
<br />
To achieve this we will need early career researcher contributions in a variety of areas at every stage of the pipeline. For example – we will need analytical chemistry experts who specialise in the analytical platforms and data acquisition, as we will need robust and reproducible data that can be translated to collaborating groups. We will also need researchers who can contribute in the bioinformatics of such projects - to combine and match data from different cohorts, and then work on integrating data acquired from the different omic technologies. By achieving this we can build giant datasets, and mine them to finely detail the mechanism of systemic diseases.<br />
<br />
Also, research into the metabolism of the human microbiome will grow (more!), we’ve already touched above on the gut-brain axis, and I think that research into host-microbe interactions at a metabolic level will be hot topics going forwards, as will combining these datasets and interpreting the interactions at a metabolite level through metabolomics, and the subsequent impact and influence on disease, will be a fascinating research area.<br />
<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Luke_Whiley&diff=1644Luke Whiley2022-04-12T05:28:50Z<p>FitriAmalia: </p>
<hr />
<div>[[Image: LukeWhiley.jpg|thumb| Luke Whiley (BSc, PhD) ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
I am a researcher based at Murdoch University, Perth, Australia and specialise in metabolism and phenomics applications in healthy ageing and dementia. Specifically, my research interests lie in identifying the systemic metabolism that underpins disease risk. I’m particularly interested in the complex interactions between genetics, lifestyle, and environment and how these interactions influence the chance of developing neurodegenerative conditions and dementias including Alzheimer’s disease. <br />
<br />
Previously, my research in the metabolic phenotyping has taken me to university research teams in the UK (King’s College London, Imperial College London) and Spain (Universidad CEU, Madrid) before arriving at Murdoch University in October 2019. I specialise in metabolic phenotyping and metabolomics using mass spectrometry, including both discovery and targeted workflows. I enjoy working and continued development of skills across the complete pipeline; from mass spectrometry method development, raw data acquisition, data pre-processing and multivariate and univariate statistical data analysis. In 2021 I was named one of the American Chemical Society’s Rising Stars in Metabolomics and Proteomics for my research.<br />
<br />
I am passionate in public outreach programs and the communication of research, and I have been involved with social media campaigns for dementia charities, including the Dementia Revolution London Marathon campaign, and have appeared on ABC Perth Radio, Pint of Science and multiple SciComm podcasts, including the Naked Scientist and Avid research.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first started down the path of metabolomics during my PhD research in 2009. My research aim was to identify blood-based biomarkers of Alzheimer’s disease. Before my PhD, I had already had some experience in analytical chemistry and small molecule LC-MS, and the PhD project had access to an LC-QToF-MS, so it was a natural fit that kicked off a metabolomics and lipidomics journey!<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
I’m currently based in Australia. I moved over from the UK in 2019 to help set up the Australian National Phenome Centre (ANPC) in Perth. Since I have been here, I have been working on building up metabolomics mass spectrometry methods and creating new collaborations, both nationally and internationally, as the centre goes through its formative years. <br />
<br />
My primary research interest in metabolomics remains in the neurodegenerative space, specifically - studying the mechanism and metabolism of neurodegeneration. The aim of this research is two fold; first, can we identify early mechanistic pathways that contribute to disease; and second to build an understanding of the wider impact of neurodegeneration on systemic metabolism. <br />
<br />
A recent interesting project that highlights this is the application of mass spectrometry metabolomics to serum collected from models of traumatic brain injury, with the aim to identify possible blood-based prognosis predictors of injury.<br />
<br />
<br />
===Question 3===<br />
<br />
''' 3. You are actively involved in neurodegenerative disease-related research, such as Alzheimer's and dementia. What are the advantages of involving metabolomics in this field? '''<br />
<br />
Our knowledge of Alzheimer’s disease is rapidly advancing all the time, but there are still some major gaps – particularly in our understanding of those who are most at risk of developing the disease and why they develop it. Although we now are adept at identifying genetic risk factors, how those risk factors translate to disease incidence and detailing the mechanisms that underpin them often remains unclear. <br />
<br />
Metabolomics gives us the opportunity to investigate this from a metabolic pathway and mechanistic viewpoint. I think over the coming years we will see much more research investigating the specific metabolic mechanisms of genetic and environmental risk of disease. This will really help us build the specific pathways that influence disease and the subsequent mechanistic picture as to why certain individuals go on to develop the disease and then perhaps we can then modify these pathways, and delay the progression of disease.<br />
<br />
===Question 4===<br />
<br />
''' 4. You often use urine or serum as the samples for untargeted metabolomics studies for phenotyping Alzheimer's and dementia diseases. What are the challenges in translating the results found using this kind of samples into a more local understanding of the nervous system once samples like CSF and brain tissue are very unavailable? '''<br />
<br />
This is certainly a huge challenge in the field – and something that is really interesting to consider when performing such research. Typically, such analysis reveals systemic changes, rather than direct metabolites of the neurodegeneration itself. The challenge to unpick these patterns that we see in the data and determine if they are in anyway causative factors in the disease or if they are a response to disease pathology itself. <br />
<br />
One such way we can attempt to address this is to work on longitudinal cohorts, and to study the metabolism of “healthy” populations, before they develop neurodegenerative diseases. By retrospectively looking at this data in combination with up-to-date current clinical data of the participants diagnostic outcome, we can try to observe metabolic patterns in populations that could indicate those who later go on to develop neurodegenerative conditions.<br />
<br />
<br />
===Question 5===<br />
<br />
''' 5. Would you mind sharing any interesting findings in the application of metabolomics in neurodegenerative disease? '''<br />
<br />
We collaborate with a group in Singapore who are interested in the influence of the gut microbiome on the host neurological system. We recently helped them by applying mass spectrometry metabolomics platforms to measure specific plasma metabolites. The project was able to demonstrate that these metabolites, secreted by gut-microbes, go on to influence adult neurogenesis. The data indicates that a symbiotic gut–brain coregulatory axis exists, connecting the metabolic status of gut microbes to the control of neurogenesis in the brain. <br />
<br />
The gut-brain axis is a really interesting area of research, and the concept that the microbes in our gut can influence our neurological system, mood and even regulate neurogenesis is fascinating.<br />
<br />
===Question 5===<br />
<br />
''' 6. What you would say are next hot topics in the field of neurodegenerative diseases that early career researchers in the field of metabolomics could strongly contribute to? '''<br />
<br />
I think data integration will become a hot (hotter?) topic in the field, both in terms of combining metabolomic data from cohorts from around the world to create larger datasets to combining different omic techniques, for example metabolomics, microbiomics, genomics. <br />
<br />
To achieve this we will need early career researcher contributions in a variety of areas at every stage of the pipeline. For example – we will need analytical chemistry experts who specialise in the analytical platforms and data acquisition, as we will need robust and reproducible data that can be translated to collaborating groups. We will also need researchers who can contribute in the bioinformatics of such projects - to combine and match data from different cohorts, and then work on integrating data acquired from the different omic technologies. By achieving this we can build giant datasets, and mine them to finely detail the mechanism of systemic diseases.<br />
<br />
Also, research into the metabolism of the human microbiome will grow (more!), we’ve already touched above on the gut-brain axis, and I think that research into host-microbe interactions at a metabolic level will be hot topics going forwards, as will combining these datasets and interpreting the interactions at a metabolite level through metabolomics, and the subsequent impact and influence on disease, will be a fascinating research area.<br />
<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Luke_Whiley&diff=1643Luke Whiley2022-04-12T05:22:26Z<p>FitriAmalia: Created page with " Luke Whiley (BSc, PhD) ==Short Biography== ''' Biography''' I am a researcher based at Murdoch University, Perth, Australia and specialis..."</p>
<hr />
<div>[[Image: LukeWhiley.jpg|thumb| Luke Whiley (BSc, PhD) ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
I am a researcher based at Murdoch University, Perth, Australia and specialise in metabolism and phenomics applications in healthy ageing and dementia. Specifically, my research interests lie in identifying the systemic metabolism that underpins disease risk. I’m particularly interested in the complex interactions between genetics, lifestyle, and environment and how these interactions influence the chance of developing neurodegenerative conditions and dementias including Alzheimer’s disease. <br />
<br />
Previously, my research in the metabolic phenotyping has taken me to university research teams in the UK (King’s College London, Imperial College London) and Spain (Universidad CEU, Madrid) before arriving at Murdoch University in October 2019. I specialise in metabolic phenotyping and metabolomics using mass spectrometry, including both discovery and targeted workflows. I enjoy working and continued development of skills across the complete pipeline; from mass spectrometry method development, raw data acquisition, data pre-processing and multivariate and univariate statistical data analysis. In 2021 I was named one of the American Chemical Society’s Rising Stars in Metabolomics and Proteomics for my research.<br />
<br />
I am passionate in public outreach programs and the communication of research, and I have been involved with social media campaigns for dementia charities, including the Dementia Revolution London Marathon campaign, and have appeared on ABC Perth Radio, Pint of Science and multiple SciComm podcasts, including the Naked Scientist and Avid research.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I studied physics until my master’s degree. I collaborated with Shimadzu to develop a mass spectrometry imaging (MSI) system in my doctoral program. I initially aimed at protein imaging, but the detection sensitivity was low, so I started phospholipids imaging in mouse brains and cancer tissues. Therefore, I can say that I introduced metabolomics (especially phospholipids analysis) to evaluate the performance of the developed instrument during my doctoral course.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Recently, I have applied MSI in various fields (biology, medicine, botany, food science). Among them, I have realized new enzyme histochemistry method with MSI [1][2] and are applying it to plant science.<br />
I am also involved in the performance evaluation and application development of a new MSI instrument, the iMScope QT (Shimadzu, Kyoto, Japan).<br />
<br />
===Question 3===<br />
<br />
''' 3. At the beginning of your career, you are involved in physics science and then changing into life sciences and biology, How do you overcome the challenges and dissimilarities between both of study? '''<br />
<br />
I get asked that question all the time. It would be interesting to hear my background. In my case, I majored in particle physics and developed instruments. Therefore, I switched fields to life sciences starting with instrumental development. The fundamentals of instrumental development are the same in any field. It simply differs in its application. For this reason, I studied instrumentation and brain science, which I was considering as a field of application at the time. At that time, I felt a big difference from physics. As I have already mentioned, I was studying particle physics. In particle physics, all phenomena are described by a very simple quantum field theory and gauge theory (the formulas are beautiful). On the other hand, I rarely saw formulas in biology. Of course, there are many different fields within biology, so I am describing one aspect of molecular biology that I worked on. At first, I was puzzled by this point, but I got used to it while doing research. In addition, I learned experimental techniques of molecular biology through research, not textbooks.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are actively involved in developing the mass spectrometry imaging (MSI) methods for various biological samples, what are the challenges in developing the MSI methods, and how did you overcome them? '''<br />
<br />
My group's motto is "Seeing is believing. I want to make the various molecules in different samples visible. However, I am not in a situation where I can see everything at this point. Furthermore, even if I could, the process would be a trial-and-error process. At present, there is no other solution. I am trying to say that no matter how good the instrument is, what is important is the sample preparation method. Fortunately, I have gained much know-how through my research so far. However, I think that is not enough. It is just my imagination, but I would like to propose optimal sample preparation using AI and other methods in the future. I do not know if it is possible. <br />
<br />
===Question 5===<br />
<br />
''' 5. Mass spectrometry imaging is indeed an interesting field, what is your advice to the early-career researcher that wants to be involved in this field? '''<br />
<br />
I think it's good that you are as interested in different fields as I am. I also did research at CERN in Geneva, Switzerland, during my master's period. The time spent at CERN allowed me to study instrumental development and theory in particle physics (Actually, I felt that the experimental and theoretical researchers were quite different!). The two years I spent immersed in research in Switzerland are still a treasure for me.<br />
<br />
Back on topic, I consider MSI to have a cross-disciplinary aspect as it can be applied to various samples. It is not just a matter of obtaining ion distributions but also of knowing the anatomy of the sample in order to interpret the data. Furthermore, in recent years, methods have been reported to analyze many mass spectra obtained by MSI, considering them as big data. I believe that anyone from basic life science researchers to information scientists can be involved in MSI research. This situation is especially remarkable in Europe and the United States.<br />
<br />
===References===<br />
1. E. Takeo, Y. Sugiura, Y. Ohnishi, H. Kishima, E. Fukusaki , S. Shimma*, Mass spectrometric enzyme histochemistry for choline acetyltransferase reveals de novo acetylcholine synthesis in rodent brain and spinal cord. ACS Chem Neurosci, 2021, 12, 2079-2087.<br />
<br />
2. E. Takeo, E. Fukusaki, S. Shimma*, Mass Spectrometric Enzyme Histochemistry Method Developed for Visualizing In Situ Cholinesterase Activity in Mus musculus and Drosophila melanogaster. Anal Chem, 2020, 92, 12379-12386.<br />
<br />
3. E. Sato, Y. Tsunokuni, M. Kaneko, D. Saigusa, R. Saito, S. Shimma, A. Sekimoto, Y. Kawana, Y. Oe, S. Ito, H. Sato, N. Takahashi, Metabolomics of a mouse model of preeclampsia induced by overexpressing soluble fms-like tyrosine kinase 1. Biochem Biophys Res Commun, 2020, 527 1064-1071.<br />
<br />
4. S. Jantrapirom, Y. Enomoto, J. Karinchai, M. Yamaguchi, H. Yoshida, E. Fukusaki, S. Shimma*, M. Yamaguchi*, The depletion of ubiquilin in Drosophila melanogaster disturbs neurochemical regulation to drive activity and behavioral deficits. Sci Rep, 2020, 10, 5689-5689.<br />
<br />
5. E. Takeo, Y. Sugiura, T. Uemura, K. Nishimoto, M. Yasuda, E. Sugiyama, S. Ohtsuki, T. Higashi, T. Nishikawa, M. Suematsu, E. Fukusaki, S. Shimma*, Tandem Mass Spectrometry Imaging Reveals Distinct Accumulation Patterns of Steroid Structural Isomers in Human Adrenal Glands. Anal Chem, 2019, 91, 8918-8925.<br />
<br />
6. E. Takeo, S. Shimma*, Development of quantitative imaging mass spectrometry (q-IMS) for drug visualization using animal tissues. Surf Interface Anal, 2019, 51, 21-26.<br />
<br />
7. Y. Sugiura, E. Takeo, S. Shimma, M. Yokota, T. Higashi, T. Seki, Y. Mizuno, M. Oya, T. Kosaka, M. Omura, T. Nishikawa, M. Suematsu, K. Nishimoto, Aldosterone and 18-Oxocortisol Coaccumulation in Aldosterone-Producing Lesions. Hypertension (Dallas, Tex. : 1979), 2018, 72, 1345-1354. <br />
<br />
8. Y. Enomoto, PN. An, M. Yamaguchi, E. Fukusaki, S. Shimma*, Mass Spectrometric Imaging of GABA in the Drosophila melanogaster Adult Head. Anal Sci, 2018, 34, 1055-1059.<br />
<br />
9. S. Shimma*, E. Takeo, E. Fukusaki, Protocol for Quantitative Imaging Mass Spectrometry. BUNSEKI KAGAKU, 2016, 65, 745-750.<br />
<br />
10. S. Shimma, HO. Kumada, H. Taniguchi, A. Konno, I. Yao, K. Furuta, T. Matsuda, S. Ito, Microscopic visualization of testosterone in mouse testis by use of imaging mass spectrometry. Anal Bioanal Chem, 2016, 408, 7607-7615.<br />
https://doi.org/10.1371/journal.pcbi.1002375<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Expert_Opinion&diff=1642Expert Opinion2022-04-12T05:21:02Z<p>FitriAmalia: </p>
<hr />
<div>The '''Expert Opinion''' is an initiative from the [[Early-Career Members Network|Early-Career Members Network (EMN) Committee]] that intends to publish career feedback from leading researchers in the metabolomics field. With that, early career researchers can get to know different specialists on the field and, more importantly, get insights and tips on how to build their on career.<br />
<br />
[[Image: LukeWhiley.jpg|75px|link= Luke Whiley]] [[Luke Whiley| Dr. Luke Whiley (April, 2022)]]<br />
<br />
[[Image: ShuichiShimma.jpg|75px|link= Shuichi Shimma]] [[Shuichi Shimma| Dr. Shuichi Shimma (March, 2022)]]<br />
<br />
[[Image: JohannesRainer.jpeg|75px|link= Johannes Rainer]] [[Johannes Rainer| Dr. Johannes Rainer (February, 2022)]]<br />
<br />
[[Image: TimEbbels.jpg|75px|link= Tim Ebbels]] [[Tim Ebbels| Dr. Tim Ebbels (January, 2022)]]<br />
<br />
[[Image: Michael Witting.jpg|75px|link= Michael Witting]] [[Michael Witting| Dr. Michael Witting (October, 2021)]]<br />
<br />
[[Image: Candice Ulmer.jpg|75px|link= Candice Ulmer]] [[Candice Ulmer| Dr. Candice Z. Ulmer (August, 2021)]]<br />
<br />
[[Image: Kati_Hanhineva2.jpg|75px|link= Kati Hanhineva]] [[Kati Hanhineva| Dr. Kati Hanhineva (May, 2021)]]<br />
<br />
[[Image: Justine_Bertrand-Michel.jpg|75px|link= Justine Bertrand-Michel]] [[Justine Bertrand-Michel|Dr. Justine Bertrand-Michel (April, 2021)]]<br />
<br />
[[Image:Pieter_Dorrestein.jpg|75px|link= Pieter Dorrestein]] [[Pieter Dorrestein|Professor Pieter Dorrestein (March, 2021)]]<br />
<br />
[[Image:Roy_Goodacre.png|75px|link= Roy Goodacre]] [[Roy Goodacre|Professor Roy Goodacre (February, 2021)]]<br />
<br />
[[Image: Kazuki_Saito.jpg|75px|link= Kazuki Saito]] [[Kazuki Saito|Dr. Kazuki Saito (January, 2021)]]<br />
<br />
[[Image: Augustin_Scalbert.jpg|75px|link= Augustin Scalbert]] [[Augustin Scalbert|Dr. Augustin Scalbert (December, 2020)]]<br />
<br />
[[Image: Jessica_LaskySu.jpg|75px|link= Jessica Lasky-Su]] [[Jessica Lasky-Su|Associate Professor Jessica Lasky-Su (February, 2020)]]<br />
<br />
[[Image: Nichole_Reisdorph.png|75px|link= Nichole Reisdorph]] [[Nichole Reisdorph|Dr Nichole Reisdorph (September, 2019)]]<br />
<br />
[[Image:RickDunn.png|75px|link= Rick Dunn]] [[Rick Dunn|Professor Warwick (Rick) Dunn (July, 2019)]]<br />
<br />
[[Image:Mark_R_Viant.png|75px|link= Mark Viant]] [[Mark Viant|Professor Mark Viant (April, 2019)]]<br />
<br />
[[Image:StaceyReinke.jpg|75px|link= Stacey Reinke]] [[Stacey Reinke|Dr Stacey Reinke (March, 2019)]]<br />
<br />
[[Image:Antonio.jpg|75px|link= Carla Antonio]] [[Carla_Antonio|Dr Carla Antonio (July, 2018)]]<br />
<br />
[[Image:Vanderhooft.jpg|75px|link= Justin van der Hooft]] [[Justin_van_der_Hooft|Dr Justin J.J. van der Hooft (February, 2018)]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=File:LukeWhiley.jpg&diff=1641File:LukeWhiley.jpg2022-04-12T05:19:57Z<p>FitriAmalia: </p>
<hr />
<div></div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Main_Page&diff=1633Main Page2022-03-08T05:26:35Z<p>FitriAmalia: </p>
<hr />
<div>__NOTOC____NOEDITSECTION__{{notitle}}<div style="position: relative; top: -30px; z-index: 100; font-size:100%;"><br />
{|cellpadding="5" cellspacing="0"|<br />
<br />
|style="border: 1px solid #DDDDDD;font-size:120%"|<br />
Welcome to the '''Early-Career Members Network (EMN) Webpage''', a resource curated by [[Early-Career_Members_Network | Early-Career Members Network of the Metabolomics Society]]. This wiki-styled page is designed to be a focal point for educational resources and online tools related to all facets of metabolomics, aiming to reach mainly young researchers of the field.<br />
<br />
<!-- NOTES FOR THE CATEGORIES TABLE:<br />
<br />
* There is *NO* paragraph break after the <br /> tags, only a single space.<br />
* Do not enter empty lines anywhere between <span...> and </center> (breaks the formatting).<br />
* Images are taken from http://en.wikipedia.org/wiki/Wikipedia:Categorical_index<br />
<br />
<br />
--><br />
<span id="Highlights"></span><br />
<center><br />
<br />
{| width=90% style="border: 2px solid #DDDDDD; background-color:rgb(250,250,255); margin-top:10px" cellspacing=20<br />
!colspan=2 style="text-align:center; font-size:100%;"|'''Highlights'''<br />
|-<br />
!colspan=2 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;padding-left:1em;"|<br />
<h3><br />
[[Image: ShuichiShimma.jpg|x140px|border|link= Shuichi Shimma]]<br /><br /> <br />
This month Expert Opinion comes from Dr [[Shuichi Shimma| Shuichi Shimma!]]<br /><br /><br />
</h3><br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;"|<br />
<h3><br />
[[Image:Conference_2022.png|x150px|border|link=Upcoming Events]]<br /><br /> <br />
Do not miss the Metabolomics Conference 2022. Click [https://www.metabolomics2022.org/ here] to know more! <br /><br /><br />
|}<br />
<br />
<span id="Regions"></span><br />
<br />
{|width=80% style="border: 2px solid #DDDDDD; margin-top:1px" cellspacing=1;"<br />
!colspan=6 style="text-align:center; font-size:100%;"|'''Finding Metabolomics Communities'''<br />
|-<br />
!colspan=6 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:16,66%; font-size:95%; vertical-align:bottom; text-align:center;"|<br />
[[Image:128px-Blank Map-Africa.svg.png|link= Metabolomics Communities#Africa|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Africa|'''Africa''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-Location Map Asia.svg.png|link= Metabolomics Communities#Asia|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Asia|'''Asia''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:BlankMap-Europe-v4.png|link= Metabolomics Communities#Europe|x100px]]<br /><br /><br />
[[Metabolomics_Communities#Europe|'''Europe''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-America_Blank.svg.png|link=Metabolomics Communities#North and Central America|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#North and Central America|'''North & Central America''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:Blank Map Oceania3.svg.png|link=Metabolomics Communities#Oceania|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Oceania|'''Oceania''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-BlankMap-South-America.png|link= Communities#South America|x100px]]<br /><br /><br />
[[Metabolomics_Communities#South America|'''South America''']] <br /><br /> <br />
|}<br />
<br />
<span id="Keep updated! Follow us"></span><br />
{| width=90% style="border: 2px solid #DDDDDD; ; margin-top:20px" cellspacing=6<br />
!colspan=3 style="text-align:center; font-size:100%;"|'''Keep updated! Follow us on social medias!'''<br />
|-<br />
!colspan=3 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:right; padding-left:1em;"|<br />
[[Image: Facebook.png|70px|link=https://www.facebook.com/EMN.MetabolomicsSociety]]<br /><br /> <br />
|style="width:20%; font-size:95%; vertical-align:center; text-align:left;"|<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:left;"|<br />
[[Image:Twitter.png|70px|link=https://twitter.com/emn_metsoc?lang=pt]]<br /><br /> <br />
</h3><br />
|}<br />
If you would like to suggest content, please contact the current EMN committee at ''info.emn@metabolomicssociety.org''<br />
|}</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Shuichi_Shimma&diff=1632Shuichi Shimma2022-03-08T05:22:10Z<p>FitriAmalia: /* Short Biography */</p>
<hr />
<div>[[Image: ShuichiShimma.jpg|thumb| Shuichi Shimma ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Shuichi Shimma received his B.S. degree in 2001 and M.S. degree in 2003 from University of Tsukuba, Japan. He completed the doctoral course at the graduate university for advanced studies, and received his Ph.D in 2007. He served as JSPS post-doctoral fellow and assistant professor at Osaka University between 2007 and 2012. From 2012, he entered National Cancer Center Research Institute in Tokyo and started to apply imaging mass spectrometry for clinical pharmacology. From 2015, he started a position of associate professor at Osaka University, Japan. His research interest is to develop instruments and applications for mass spectrometry imaging in plant and food science, medical science to visualize biomolecules (biological metabolites) and drugs. He is also an Associate Professor in Osaka University, Japan.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I studied physics until my master’s degree. I collaborated with Shimadzu to develop a mass spectrometry imaging (MSI) system in my doctoral program. I initially aimed at protein imaging, but the detection sensitivity was low, so I started phospholipids imaging in mouse brains and cancer tissues. Therefore, I can say that I introduced metabolomics (especially phospholipids analysis) to evaluate the performance of the developed instrument during my doctoral course.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Recently, I have applied MSI in various fields (biology, medicine, botany, food science). Among them, I have realized new enzyme histochemistry method with MSI [1][2] and are applying it to plant science.<br />
I am also involved in the performance evaluation and application development of a new MSI instrument, the iMScope QT (Shimadzu, Kyoto, Japan).<br />
<br />
===Question 3===<br />
<br />
''' 3. At the beginning of your career, you are involved in physics science and then changing into life sciences and biology, How do you overcome the challenges and dissimilarities between both of study? '''<br />
<br />
I get asked that question all the time. It would be interesting to hear my background. In my case, I majored in particle physics and developed instruments. Therefore, I switched fields to life sciences starting with instrumental development. The fundamentals of instrumental development are the same in any field. It simply differs in its application. For this reason, I studied instrumentation and brain science, which I was considering as a field of application at the time. At that time, I felt a big difference from physics. As I have already mentioned, I was studying particle physics. In particle physics, all phenomena are described by a very simple quantum field theory and gauge theory (the formulas are beautiful). On the other hand, I rarely saw formulas in biology. Of course, there are many different fields within biology, so I am describing one aspect of molecular biology that I worked on. At first, I was puzzled by this point, but I got used to it while doing research. In addition, I learned experimental techniques of molecular biology through research, not textbooks.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are actively involved in developing the mass spectrometry imaging (MSI) methods for various biological samples, what are the challenges in developing the MSI methods, and how did you overcome them? '''<br />
<br />
My group's motto is "Seeing is believing. I want to make the various molecules in different samples visible. However, I am not in a situation where I can see everything at this point. Furthermore, even if I could, the process would be a trial-and-error process. At present, there is no other solution. I am trying to say that no matter how good the instrument is, what is important is the sample preparation method. Fortunately, I have gained much know-how through my research so far. However, I think that is not enough. It is just my imagination, but I would like to propose optimal sample preparation using AI and other methods in the future. I do not know if it is possible. <br />
<br />
===Question 5===<br />
<br />
''' 5. Mass spectrometry imaging is indeed an interesting field, what is your advice to the early-career researcher that wants to be involved in this field? '''<br />
<br />
I think it's good that you are as interested in different fields as I am. I also did research at CERN in Geneva, Switzerland, during my master's period. The time spent at CERN allowed me to study instrumental development and theory in particle physics (Actually, I felt that the experimental and theoretical researchers were quite different!). The two years I spent immersed in research in Switzerland are still a treasure for me.<br />
<br />
Back on topic, I consider MSI to have a cross-disciplinary aspect as it can be applied to various samples. It is not just a matter of obtaining ion distributions but also of knowing the anatomy of the sample in order to interpret the data. Furthermore, in recent years, methods have been reported to analyze many mass spectra obtained by MSI, considering them as big data. I believe that anyone from basic life science researchers to information scientists can be involved in MSI research. This situation is especially remarkable in Europe and the United States.<br />
<br />
===References===<br />
1. E. Takeo, Y. Sugiura, Y. Ohnishi, H. Kishima, E. Fukusaki , S. Shimma*, Mass spectrometric enzyme histochemistry for choline acetyltransferase reveals de novo acetylcholine synthesis in rodent brain and spinal cord. ACS Chem Neurosci, 2021, 12, 2079-2087.<br />
<br />
2. E. Takeo, E. Fukusaki, S. Shimma*, Mass Spectrometric Enzyme Histochemistry Method Developed for Visualizing In Situ Cholinesterase Activity in Mus musculus and Drosophila melanogaster. Anal Chem, 2020, 92, 12379-12386.<br />
<br />
3. E. Sato, Y. Tsunokuni, M. Kaneko, D. Saigusa, R. Saito, S. Shimma, A. Sekimoto, Y. Kawana, Y. Oe, S. Ito, H. Sato, N. Takahashi, Metabolomics of a mouse model of preeclampsia induced by overexpressing soluble fms-like tyrosine kinase 1. Biochem Biophys Res Commun, 2020, 527 1064-1071.<br />
<br />
4. S. Jantrapirom, Y. Enomoto, J. Karinchai, M. Yamaguchi, H. Yoshida, E. Fukusaki, S. Shimma*, M. Yamaguchi*, The depletion of ubiquilin in Drosophila melanogaster disturbs neurochemical regulation to drive activity and behavioral deficits. Sci Rep, 2020, 10, 5689-5689.<br />
<br />
5. E. Takeo, Y. Sugiura, T. Uemura, K. Nishimoto, M. Yasuda, E. Sugiyama, S. Ohtsuki, T. Higashi, T. Nishikawa, M. Suematsu, E. Fukusaki, S. Shimma*, Tandem Mass Spectrometry Imaging Reveals Distinct Accumulation Patterns of Steroid Structural Isomers in Human Adrenal Glands. Anal Chem, 2019, 91, 8918-8925.<br />
<br />
6. E. Takeo, S. Shimma*, Development of quantitative imaging mass spectrometry (q-IMS) for drug visualization using animal tissues. Surf Interface Anal, 2019, 51, 21-26.<br />
<br />
7. Y. Sugiura, E. Takeo, S. Shimma, M. Yokota, T. Higashi, T. Seki, Y. Mizuno, M. Oya, T. Kosaka, M. Omura, T. Nishikawa, M. Suematsu, K. Nishimoto, Aldosterone and 18-Oxocortisol Coaccumulation in Aldosterone-Producing Lesions. Hypertension (Dallas, Tex. : 1979), 2018, 72, 1345-1354. <br />
<br />
8. Y. Enomoto, PN. An, M. Yamaguchi, E. Fukusaki, S. Shimma*, Mass Spectrometric Imaging of GABA in the Drosophila melanogaster Adult Head. Anal Sci, 2018, 34, 1055-1059.<br />
<br />
9. S. Shimma*, E. Takeo, E. Fukusaki, Protocol for Quantitative Imaging Mass Spectrometry. BUNSEKI KAGAKU, 2016, 65, 745-750.<br />
<br />
10. S. Shimma, HO. Kumada, H. Taniguchi, A. Konno, I. Yao, K. Furuta, T. Matsuda, S. Ito, Microscopic visualization of testosterone in mouse testis by use of imaging mass spectrometry. Anal Bioanal Chem, 2016, 408, 7607-7615.<br />
https://doi.org/10.1371/journal.pcbi.1002375<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Shuichi_Shimma&diff=1631Shuichi Shimma2022-03-08T05:20:59Z<p>FitriAmalia: </p>
<hr />
<div>[[Image: ShuichiShimma.jpg|thumb| Shuichi Shimma ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Shuichi Shimma received his B.S. degree in 2001 and M.S. degree in 2003 from University of Tsukuba, Japan. He completed the doctoral course at the graduate university for advanced studies, and received his Ph.D in 2007. He served as JSPS post-doctoral fellow and assistant professor at Osaka University between 2007 and 2012. From 2012, he entered National Cancer Center Research Institute in Tokyo and started to apply imaging mass spectrometry for clinical pharmacology. From 2015, he started a position of associate professor at Osaka University, Japan. His research interest is to develop instruments and applications for mass spectrometry imaging in plant and food science, medical science to visualize biomolecules (biological metabolites) and drugs.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I studied physics until my master’s degree. I collaborated with Shimadzu to develop a mass spectrometry imaging (MSI) system in my doctoral program. I initially aimed at protein imaging, but the detection sensitivity was low, so I started phospholipids imaging in mouse brains and cancer tissues. Therefore, I can say that I introduced metabolomics (especially phospholipids analysis) to evaluate the performance of the developed instrument during my doctoral course.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Recently, I have applied MSI in various fields (biology, medicine, botany, food science). Among them, I have realized new enzyme histochemistry method with MSI [1][2] and are applying it to plant science.<br />
I am also involved in the performance evaluation and application development of a new MSI instrument, the iMScope QT (Shimadzu, Kyoto, Japan).<br />
<br />
===Question 3===<br />
<br />
''' 3. At the beginning of your career, you are involved in physics science and then changing into life sciences and biology, How do you overcome the challenges and dissimilarities between both of study? '''<br />
<br />
I get asked that question all the time. It would be interesting to hear my background. In my case, I majored in particle physics and developed instruments. Therefore, I switched fields to life sciences starting with instrumental development. The fundamentals of instrumental development are the same in any field. It simply differs in its application. For this reason, I studied instrumentation and brain science, which I was considering as a field of application at the time. At that time, I felt a big difference from physics. As I have already mentioned, I was studying particle physics. In particle physics, all phenomena are described by a very simple quantum field theory and gauge theory (the formulas are beautiful). On the other hand, I rarely saw formulas in biology. Of course, there are many different fields within biology, so I am describing one aspect of molecular biology that I worked on. At first, I was puzzled by this point, but I got used to it while doing research. In addition, I learned experimental techniques of molecular biology through research, not textbooks.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are actively involved in developing the mass spectrometry imaging (MSI) methods for various biological samples, what are the challenges in developing the MSI methods, and how did you overcome them? '''<br />
<br />
My group's motto is "Seeing is believing. I want to make the various molecules in different samples visible. However, I am not in a situation where I can see everything at this point. Furthermore, even if I could, the process would be a trial-and-error process. At present, there is no other solution. I am trying to say that no matter how good the instrument is, what is important is the sample preparation method. Fortunately, I have gained much know-how through my research so far. However, I think that is not enough. It is just my imagination, but I would like to propose optimal sample preparation using AI and other methods in the future. I do not know if it is possible. <br />
<br />
===Question 5===<br />
<br />
''' 5. Mass spectrometry imaging is indeed an interesting field, what is your advice to the early-career researcher that wants to be involved in this field? '''<br />
<br />
I think it's good that you are as interested in different fields as I am. I also did research at CERN in Geneva, Switzerland, during my master's period. The time spent at CERN allowed me to study instrumental development and theory in particle physics (Actually, I felt that the experimental and theoretical researchers were quite different!). The two years I spent immersed in research in Switzerland are still a treasure for me.<br />
<br />
Back on topic, I consider MSI to have a cross-disciplinary aspect as it can be applied to various samples. It is not just a matter of obtaining ion distributions but also of knowing the anatomy of the sample in order to interpret the data. Furthermore, in recent years, methods have been reported to analyze many mass spectra obtained by MSI, considering them as big data. I believe that anyone from basic life science researchers to information scientists can be involved in MSI research. This situation is especially remarkable in Europe and the United States.<br />
<br />
===References===<br />
1. E. Takeo, Y. Sugiura, Y. Ohnishi, H. Kishima, E. Fukusaki , S. Shimma*, Mass spectrometric enzyme histochemistry for choline acetyltransferase reveals de novo acetylcholine synthesis in rodent brain and spinal cord. ACS Chem Neurosci, 2021, 12, 2079-2087.<br />
<br />
2. E. Takeo, E. Fukusaki, S. Shimma*, Mass Spectrometric Enzyme Histochemistry Method Developed for Visualizing In Situ Cholinesterase Activity in Mus musculus and Drosophila melanogaster. Anal Chem, 2020, 92, 12379-12386.<br />
<br />
3. E. Sato, Y. Tsunokuni, M. Kaneko, D. Saigusa, R. Saito, S. Shimma, A. Sekimoto, Y. Kawana, Y. Oe, S. Ito, H. Sato, N. Takahashi, Metabolomics of a mouse model of preeclampsia induced by overexpressing soluble fms-like tyrosine kinase 1. Biochem Biophys Res Commun, 2020, 527 1064-1071.<br />
<br />
4. S. Jantrapirom, Y. Enomoto, J. Karinchai, M. Yamaguchi, H. Yoshida, E. Fukusaki, S. Shimma*, M. Yamaguchi*, The depletion of ubiquilin in Drosophila melanogaster disturbs neurochemical regulation to drive activity and behavioral deficits. Sci Rep, 2020, 10, 5689-5689.<br />
<br />
5. E. Takeo, Y. Sugiura, T. Uemura, K. Nishimoto, M. Yasuda, E. Sugiyama, S. Ohtsuki, T. Higashi, T. Nishikawa, M. Suematsu, E. Fukusaki, S. Shimma*, Tandem Mass Spectrometry Imaging Reveals Distinct Accumulation Patterns of Steroid Structural Isomers in Human Adrenal Glands. Anal Chem, 2019, 91, 8918-8925.<br />
<br />
6. E. Takeo, S. Shimma*, Development of quantitative imaging mass spectrometry (q-IMS) for drug visualization using animal tissues. Surf Interface Anal, 2019, 51, 21-26.<br />
<br />
7. Y. Sugiura, E. Takeo, S. Shimma, M. Yokota, T. Higashi, T. Seki, Y. Mizuno, M. Oya, T. Kosaka, M. Omura, T. Nishikawa, M. Suematsu, K. Nishimoto, Aldosterone and 18-Oxocortisol Coaccumulation in Aldosterone-Producing Lesions. Hypertension (Dallas, Tex. : 1979), 2018, 72, 1345-1354. <br />
<br />
8. Y. Enomoto, PN. An, M. Yamaguchi, E. Fukusaki, S. Shimma*, Mass Spectrometric Imaging of GABA in the Drosophila melanogaster Adult Head. Anal Sci, 2018, 34, 1055-1059.<br />
<br />
9. S. Shimma*, E. Takeo, E. Fukusaki, Protocol for Quantitative Imaging Mass Spectrometry. BUNSEKI KAGAKU, 2016, 65, 745-750.<br />
<br />
10. S. Shimma, HO. Kumada, H. Taniguchi, A. Konno, I. Yao, K. Furuta, T. Matsuda, S. Ito, Microscopic visualization of testosterone in mouse testis by use of imaging mass spectrometry. Anal Bioanal Chem, 2016, 408, 7607-7615.<br />
https://doi.org/10.1371/journal.pcbi.1002375<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Shuichi_Shimma&diff=1630Shuichi Shimma2022-03-08T05:20:11Z<p>FitriAmalia: /* References */</p>
<hr />
<div>[[Image: ShuichiShimma.jpg|thumb| Shuichi Shimma ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Shuichi Shimma received his B.S. degree in 2001 and M.S. degree in 2003 from University of Tsukuba, Japan. He completed the doctoral course at the graduate university for advanced studies, and received his Ph.D in 2007. He served as JSPS post-doctoral fellow and assistant professor at Osaka University between 2007 and 2012. From 2012, he entered National Cancer Center Research Institute in Tokyo and started to apply imaging mass spectrometry for clinical pharmacology. From 2015, he started a position of associate professor at Osaka University, Japan. His research interest is to develop instruments and applications for mass spectrometry imaging in plant and food science, medical science to visualize biomolecules (biological metabolites) and drugs.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I studied physics until my master’s degree. I collaborated with Shimadzu to develop a mass spectrometry imaging (MSI) system in my doctoral program. I initially aimed at protein imaging, but the detection sensitivity was low, so I started phospholipids imaging in mouse brains and cancer tissues. Therefore, I can say that I introduced metabolomics (especially phospholipids analysis) to evaluate the performance of the developed instrument during my doctoral course.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Recently, I have applied MSI in various fields (biology, medicine, botany, food science). Among them, I have realized new enzyme histochemistry method with MSI [1][2] and are applying it to plant science.<br />
I am also involved in the performance evaluation and application development of a new MSI instrument, the iMScope QT (Shimadzu, Kyoto, Japan).<br />
<br />
<br />
===Question 3===<br />
<br />
''' 3. At the beginning of your career, you are involved in physics science and then changing into life sciences and biology, How do you overcome the challenges and dissimilarities between both of study? '''<br />
<br />
I get asked that question all the time. It would be interesting to hear my background. In my case, I majored in particle physics and developed instruments. Therefore, I switched fields to life sciences starting with instrumental development. The fundamentals of instrumental development are the same in any field. It simply differs in its application. For this reason, I studied instrumentation and brain science, which I was considering as a field of application at the time. At that time, I felt a big difference from physics. As I have already mentioned, I was studying particle physics. In particle physics, all phenomena are described by a very simple quantum field theory and gauge theory (the formulas are beautiful). On the other hand, I rarely saw formulas in biology. Of course, there are many different fields within biology, so I am describing one aspect of molecular biology that I worked on. At first, I was puzzled by this point, but I got used to it while doing research. In addition, I learned experimental techniques of molecular biology through research, not textbooks.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are actively involved in developing the mass spectrometry imaging (MSI) methods for various biological samples, what are the challenges in developing the MSI methods, and how did you overcome them? '''<br />
<br />
My group's motto is "Seeing is believing. I want to make the various molecules in different samples visible. However, I am not in a situation where I can see everything at this point. Furthermore, even if I could, the process would be a trial-and-error process. At present, there is no other solution. I am trying to say that no matter how good the instrument is, what is important is the sample preparation method. Fortunately, I have gained much know-how through my research so far. However, I think that is not enough. It is just my imagination, but I would like to propose optimal sample preparation using AI and other methods in the future. I do not know if it is possible. <br />
<br />
===Question 5===<br />
<br />
''' 5. Mass spectrometry imaging is indeed an interesting field, what is your advice to the early-career researcher that wants to be involved in this field? '''<br />
<br />
I think it's good that you are as interested in different fields as I am. I also did research at CERN in Geneva, Switzerland, during my master's period. The time spent at CERN allowed me to study instrumental development and theory in particle physics (Actually, I felt that the experimental and theoretical researchers were quite different!). The two years I spent immersed in research in Switzerland are still a treasure for me.<br />
<br />
Back on topic, I consider MSI to have a cross-disciplinary aspect as it can be applied to various samples. It is not just a matter of obtaining ion distributions but also of knowing the anatomy of the sample in order to interpret the data. Furthermore, in recent years, methods have been reported to analyze many mass spectra obtained by MSI, considering them as big data. I believe that anyone from basic life science researchers to information scientists can be involved in MSI research. This situation is especially remarkable in Europe and the United States.<br />
<br />
===References===<br />
1. E. Takeo, Y. Sugiura, Y. Ohnishi, H. Kishima, E. Fukusaki , S. Shimma*, Mass spectrometric enzyme histochemistry for choline acetyltransferase reveals de novo acetylcholine synthesis in rodent brain and spinal cord. ACS Chem Neurosci, 2021, 12, 2079-2087.<br />
<br />
2. E. Takeo, E. Fukusaki, S. Shimma*, Mass Spectrometric Enzyme Histochemistry Method Developed for Visualizing In Situ Cholinesterase Activity in Mus musculus and Drosophila melanogaster. Anal Chem, 2020, 92, 12379-12386.<br />
<br />
3. E. Sato, Y. Tsunokuni, M. Kaneko, D. Saigusa, R. Saito, S. Shimma, A. Sekimoto, Y. Kawana, Y. Oe, S. Ito, H. Sato, N. Takahashi, Metabolomics of a mouse model of preeclampsia induced by overexpressing soluble fms-like tyrosine kinase 1. Biochem Biophys Res Commun, 2020, 527 1064-1071.<br />
<br />
4. S. Jantrapirom, Y. Enomoto, J. Karinchai, M. Yamaguchi, H. Yoshida, E. Fukusaki, S. Shimma*, M. Yamaguchi*, The depletion of ubiquilin in Drosophila melanogaster disturbs neurochemical regulation to drive activity and behavioral deficits. Sci Rep, 2020, 10, 5689-5689.<br />
<br />
5. E. Takeo, Y. Sugiura, T. Uemura, K. Nishimoto, M. Yasuda, E. Sugiyama, S. Ohtsuki, T. Higashi, T. Nishikawa, M. Suematsu, E. Fukusaki, S. Shimma*, Tandem Mass Spectrometry Imaging Reveals Distinct Accumulation Patterns of Steroid Structural Isomers in Human Adrenal Glands. Anal Chem, 2019, 91, 8918-8925.<br />
<br />
6. E. Takeo, S. Shimma*, Development of quantitative imaging mass spectrometry (q-IMS) for drug visualization using animal tissues. Surf Interface Anal, 2019, 51, 21-26.<br />
<br />
7. Y. Sugiura, E. Takeo, S. Shimma, M. Yokota, T. Higashi, T. Seki, Y. Mizuno, M. Oya, T. Kosaka, M. Omura, T. Nishikawa, M. Suematsu, K. Nishimoto, Aldosterone and 18-Oxocortisol Coaccumulation in Aldosterone-Producing Lesions. Hypertension (Dallas, Tex. : 1979), 2018, 72, 1345-1354. <br />
<br />
8. Y. Enomoto, PN. An, M. Yamaguchi, E. Fukusaki, S. Shimma*, Mass Spectrometric Imaging of GABA in the Drosophila melanogaster Adult Head. Anal Sci, 2018, 34, 1055-1059.<br />
<br />
9. S. Shimma*, E. Takeo, E. Fukusaki, Protocol for Quantitative Imaging Mass Spectrometry. BUNSEKI KAGAKU, 2016, 65, 745-750.<br />
<br />
10. S. Shimma, HO. Kumada, H. Taniguchi, A. Konno, I. Yao, K. Furuta, T. Matsuda, S. Ito, Microscopic visualization of testosterone in mouse testis by use of imaging mass spectrometry. Anal Bioanal Chem, 2016, 408, 7607-7615.<br />
https://doi.org/10.1371/journal.pcbi.1002375<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Shuichi_Shimma&diff=1629Shuichi Shimma2022-03-08T05:19:06Z<p>FitriAmalia: </p>
<hr />
<div>[[Image: ShuichiShimma.jpg|thumb| Shuichi Shimma ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Shuichi Shimma received his B.S. degree in 2001 and M.S. degree in 2003 from University of Tsukuba, Japan. He completed the doctoral course at the graduate university for advanced studies, and received his Ph.D in 2007. He served as JSPS post-doctoral fellow and assistant professor at Osaka University between 2007 and 2012. From 2012, he entered National Cancer Center Research Institute in Tokyo and started to apply imaging mass spectrometry for clinical pharmacology. From 2015, he started a position of associate professor at Osaka University, Japan. His research interest is to develop instruments and applications for mass spectrometry imaging in plant and food science, medical science to visualize biomolecules (biological metabolites) and drugs.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I studied physics until my master’s degree. I collaborated with Shimadzu to develop a mass spectrometry imaging (MSI) system in my doctoral program. I initially aimed at protein imaging, but the detection sensitivity was low, so I started phospholipids imaging in mouse brains and cancer tissues. Therefore, I can say that I introduced metabolomics (especially phospholipids analysis) to evaluate the performance of the developed instrument during my doctoral course.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Recently, I have applied MSI in various fields (biology, medicine, botany, food science). Among them, I have realized new enzyme histochemistry method with MSI [1][2] and are applying it to plant science.<br />
I am also involved in the performance evaluation and application development of a new MSI instrument, the iMScope QT (Shimadzu, Kyoto, Japan).<br />
<br />
<br />
===Question 3===<br />
<br />
''' 3. At the beginning of your career, you are involved in physics science and then changing into life sciences and biology, How do you overcome the challenges and dissimilarities between both of study? '''<br />
<br />
I get asked that question all the time. It would be interesting to hear my background. In my case, I majored in particle physics and developed instruments. Therefore, I switched fields to life sciences starting with instrumental development. The fundamentals of instrumental development are the same in any field. It simply differs in its application. For this reason, I studied instrumentation and brain science, which I was considering as a field of application at the time. At that time, I felt a big difference from physics. As I have already mentioned, I was studying particle physics. In particle physics, all phenomena are described by a very simple quantum field theory and gauge theory (the formulas are beautiful). On the other hand, I rarely saw formulas in biology. Of course, there are many different fields within biology, so I am describing one aspect of molecular biology that I worked on. At first, I was puzzled by this point, but I got used to it while doing research. In addition, I learned experimental techniques of molecular biology through research, not textbooks.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are actively involved in developing the mass spectrometry imaging (MSI) methods for various biological samples, what are the challenges in developing the MSI methods, and how did you overcome them? '''<br />
<br />
My group's motto is "Seeing is believing. I want to make the various molecules in different samples visible. However, I am not in a situation where I can see everything at this point. Furthermore, even if I could, the process would be a trial-and-error process. At present, there is no other solution. I am trying to say that no matter how good the instrument is, what is important is the sample preparation method. Fortunately, I have gained much know-how through my research so far. However, I think that is not enough. It is just my imagination, but I would like to propose optimal sample preparation using AI and other methods in the future. I do not know if it is possible. <br />
<br />
===Question 5===<br />
<br />
''' 5. Mass spectrometry imaging is indeed an interesting field, what is your advice to the early-career researcher that wants to be involved in this field? '''<br />
<br />
I think it's good that you are as interested in different fields as I am. I also did research at CERN in Geneva, Switzerland, during my master's period. The time spent at CERN allowed me to study instrumental development and theory in particle physics (Actually, I felt that the experimental and theoretical researchers were quite different!). The two years I spent immersed in research in Switzerland are still a treasure for me.<br />
<br />
Back on topic, I consider MSI to have a cross-disciplinary aspect as it can be applied to various samples. It is not just a matter of obtaining ion distributions but also of knowing the anatomy of the sample in order to interpret the data. Furthermore, in recent years, methods have been reported to analyze many mass spectra obtained by MSI, considering them as big data. I believe that anyone from basic life science researchers to information scientists can be involved in MSI research. This situation is especially remarkable in Europe and the United States.<br />
<br />
===References===<br />
1.E. Takeo, Y. Sugiura, Y. Ohnishi, H. Kishima, E. Fukusaki , S. Shimma*, Mass spectrometric enzyme histochemistry for choline acetyltransferase reveals de novo acetylcholine synthesis in rodent brain and spinal cord. ACS Chem Neurosci, 2021, 12, 2079-2087.<br />
<br />
2.E. Takeo, E. Fukusaki, S. Shimma*, Mass Spectrometric Enzyme Histochemistry Method Developed for Visualizing In Situ Cholinesterase Activity in Mus musculus and Drosophila melanogaster. Anal Chem, 2020, 92, 12379-12386.<br />
<br />
3.E. Sato, Y. Tsunokuni, M. Kaneko, D. Saigusa, R. Saito, S. Shimma, A. Sekimoto, Y. Kawana, Y. Oe, S. Ito, H. Sato, N. Takahashi, Metabolomics of a mouse model of preeclampsia induced by overexpressing soluble fms-like tyrosine kinase 1. Biochem Biophys Res Commun, 2020, 527 1064-1071.<br />
<br />
4.S. Jantrapirom, Y. Enomoto, J. Karinchai, M. Yamaguchi, H. Yoshida, E. Fukusaki, S. Shimma*, M. Yamaguchi*, The depletion of ubiquilin in Drosophila melanogaster disturbs neurochemical regulation to drive activity and behavioral deficits. Sci Rep, 2020, 10, 5689-5689.<br />
<br />
5.E. Takeo, Y. Sugiura, T. Uemura, K. Nishimoto, M. Yasuda, E. Sugiyama, S. Ohtsuki, T. Higashi, T. Nishikawa, M. Suematsu, E. Fukusaki, S. Shimma*, Tandem Mass Spectrometry Imaging Reveals Distinct Accumulation Patterns of Steroid Structural Isomers in Human Adrenal Glands. Anal Chem, 2019, 91, 8918-8925.<br />
<br />
6.E. Takeo, S. Shimma*, Development of quantitative imaging mass spectrometry (q-IMS) for drug visualization using animal tissues. Surf Interface Anal, 2019, 51, 21-26.<br />
<br />
7.Y. Sugiura, E. Takeo, S. Shimma, M. Yokota, T. Higashi, T. Seki, Y. Mizuno, M. Oya, T. Kosaka, M. Omura, T. Nishikawa, M. Suematsu, K. Nishimoto, Aldosterone and 18-Oxocortisol Coaccumulation in Aldosterone-Producing Lesions. Hypertension (Dallas, Tex. : 1979), 2018, 72, 1345-1354. <br />
<br />
8.Y. Enomoto, PN. An, M. Yamaguchi, E. Fukusaki, S. Shimma*, Mass Spectrometric Imaging of GABA in the Drosophila melanogaster Adult Head. Anal Sci, 2018, 34, 1055-1059.<br />
<br />
9.S. Shimma*, E. Takeo, E. Fukusaki, Protocol for Quantitative Imaging Mass Spectrometry. BUNSEKI KAGAKU, 2016, 65, 745-750.<br />
<br />
10.S. Shimma, HO. Kumada, H. Taniguchi, A. Konno, I. Yao, K. Furuta, T. Matsuda, S. Ito, Microscopic visualization of testosterone in mouse testis by use of imaging mass spectrometry. Anal Bioanal Chem, 2016, 408, 7607-7615.<br />
https://doi.org/10.1371/journal.pcbi.1002375<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Shuichi_Shimma&diff=1628Shuichi Shimma2022-03-08T05:16:04Z<p>FitriAmalia: </p>
<hr />
<div>[[Image: ShuichiShimma.jpg|thumb| Shuichi Shimma ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Shuichi Shimma received his B.S. degree in 2001 and M.S. degree in 2003 from University of Tsukuba, Japan. He completed the doctoral course at the graduate university for advanced studies, and received his Ph.D in 2007. He served as JSPS post-doctoral fellow and assistant professor at Osaka University between 2007 and 2012. From 2012, he entered National Cancer Center Research Institute in Tokyo and started to apply imaging mass spectrometry for clinical pharmacology. From 2015, he started a position of associate professor at Osaka University, Japan. His research interest is to develop instruments and applications for mass spectrometry imaging in plant and food science, medical science to visualize biomolecules (biological metabolites) and drugs.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I studied physics until my master’s degree. I collaborated with Shimadzu to develop a mass spectrometry imaging (MSI) system in my doctoral program. I initially aimed at protein imaging, but the detection sensitivity was low, so I started phospholipids imaging in mouse brains and cancer tissues. Therefore, I can say that I introduced metabolomics (especially phospholipids analysis) to evaluate the performance of the developed instrument during my doctoral course.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Recently, I have applied MSI in various fields (biology, medicine, botany, food science). Among them, I have realized new enzyme histochemistry method with MSI (Takeo et al. Anal Chem 2020 and Takeo et al. ACS Chem Neurosci 2021) and are applying it to plant science.<br />
I am also involved in the performance evaluation and application development of a new MSI instrument, the iMScope QT (Shimadzu, Kyoto, Japan).<br />
<br />
<br />
===Question 3===<br />
<br />
''' 3. At the beginning of your career, you are involved in physics science and then changing into life sciences and biology, How do you overcome the challenges and dissimilarities between both of study? '''<br />
<br />
I get asked that question all the time. It would be interesting to hear my background. In my case, I majored in particle physics and developed instruments. Therefore, I switched fields to life sciences starting with instrumental development. The fundamentals of instrumental development are the same in any field. It simply differs in its application. For this reason, I studied instrumentation and brain science, which I was considering as a field of application at the time. At that time, I felt a big difference from physics. As I have already mentioned, I was studying particle physics. In particle physics, all phenomena are described by a very simple quantum field theory and gauge theory (the formulas are beautiful). On the other hand, I rarely saw formulas in biology. Of course, there are many different fields within biology, so I am describing one aspect of molecular biology that I worked on. At first, I was puzzled by this point, but I got used to it while doing research. In addition, I learned experimental techniques of molecular biology through research, not textbooks.<br />
<br />
===Question 4===<br />
<br />
''' 4. You are actively involved in developing the mass spectrometry imaging (MSI) methods for various biological samples, what are the challenges in developing the MSI methods, and how did you overcome them? '''<br />
<br />
My group's motto is "Seeing is believing. I want to make the various molecules in different samples visible. However, I am not in a situation where I can see everything at this point. Furthermore, even if I could, the process would be a trial-and-error process. At present, there is no other solution. I am trying to say that no matter how good the instrument is, what is important is the sample preparation method. Fortunately, I have gained much know-how through my research so far. However, I think that is not enough. It is just my imagination, but I would like to propose optimal sample preparation using AI and other methods in the future. I do not know if it is possible. <br />
<br />
===Question 5===<br />
<br />
''' 5. Mass spectrometry imaging is indeed an interesting field, what is your advice to the early-career researcher that wants to be involved in this field? '''<br />
<br />
I think it's good that you are as interested in different fields as I am. I also did research at CERN in Geneva, Switzerland, during my master's period. The time spent at CERN allowed me to study instrumental development and theory in particle physics (Actually, I felt that the experimental and theoretical researchers were quite different!). The two years I spent immersed in research in Switzerland are still a treasure for me.<br />
<br />
Back on topic, I consider MSI to have a cross-disciplinary aspect as it can be applied to various samples. It is not just a matter of obtaining ion distributions but also of knowing the anatomy of the sample in order to interpret the data. Furthermore, in recent years, methods have been reported to analyze many mass spectra obtained by MSI, considering them as big data. I believe that anyone from basic life science researchers to information scientists can be involved in MSI research. This situation is especially remarkable in Europe and the United States.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Shuichi_Shimma&diff=1627Shuichi Shimma2022-03-08T05:12:00Z<p>FitriAmalia: Created page with " Shuichi Shimma ==Short Biography== ''' Biography''' Johannes studied Electrical and Biomedical Engineering at the Technical University..."</p>
<hr />
<div>[[Image: ShuichiShimma.jpg|thumb| Shuichi Shimma ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Johannes studied Electrical and Biomedical Engineering at the Technical University of Graz, Austria. He obtained his MSc in Bioinformatics in 2003 and after that conducted a PhD in Bioinformatics with a focus on cancer research in particular childhood leukemia. From 2007 to 2015 he was working, first as a Post Doc and then as a junior group leader for Bioinformatics, at the Medical University of Innsbruck, Austria. His main research areas during this time were transcriptomics and genomics in the field of childhood leukemia. In 2015 he moved to the Institute for Biomedicine of the Eurac Research in Bolzano, Italy and shifted his focus first on genetics and subsequently to metabolomics research. In 2018 he became the head of the Computational Metabolomics Team of the Institute for Biomedicine at Eurac Research. Johannes has a long-lasting experience in open software development in the fields of transcriptomics, genomics, and metabolomics. Since 2020 he got more involved in the Bioconductor project and is since a member of the Community Advisory Board, the Code of Conduct Committee, and the Package Review Working Group. He is author of, and contributor to more than 15 Bioconductor packages most of them providing functionality for the analysis of mass spectrometry and metabolomics data. In his free time, he enjoys designing stickers and logos, mountaineering and spending time with his family.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first got in contact with metabolomics data when I joined the Institute for Biomedicine of Eurac Research. I had long lasting experience in the analysis of large-scale data sets (mostly microarray and RNA-seq data) and was thus appointed to help analyzing the metabolomics data sets that were generated at the Institute, in particular the untargeted LC-MS data. I started investigating and looking for tools to analyze that data and had the impression that the software available at that time, especially when compared to the software for the processing of transcriptome data, was sub-optimal. This was when I then first contacted Steffen Neumann and Laurent Gatto and discussed with them the possibility to join forces to update and improve MS-related software in R. In particular, I wanted to avoid the code-duplication being present in the various software packages and to unify the code base of R/Bioconductor packages for the analysis of mass spectrometry (MS) data (both for metabolomics and proteomics). The rest is history. We've updated since the xcms and MSnbase R packages to support also the analysis of very large data sets and from there, started to implement, together with an ever-growing number of collaborators and contributors, a large panel of other software packages that together, as we believe, provide a comprehensive and flexible infrastructure for MS data handling and analysis.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Recently, we've implemented a set of R packages providing established methods and core functionality for the annotation of untargeted metabolomics data. Rather than being a single application, these packages provide modular functions that can be used to create customized, flexible, and reproducible annotation workflows. In addition, we're currently analyzing the targeted and untargeted metabolomics data sets from our in-house population study.<br />
<br />
===Question 3===<br />
<br />
''' 3. What are the main challenges you see on the data analysis of untargeted metabolomics data from populational studies? '''<br />
<br />
It's their magnitude. On one hand this data is computationally intense, but that's something we can easily work on and fix by simply implement more efficient or less memory demanding software. The bigger problem for me is that such data tends to be so large that it becomes hard to do a proper and comprehensive quality control. And that is obviously essential if we want to evaluate whether the pre-processing (peak detection, alignment, and correspondence) actually worked for all files. Another important fact, which however also applies to targeted metabolomics data, is that data from population studies will always be less controlled than for example data in case-control or clinical studies. Hence, evaluating influences of potential confounding factors is in my opinion very important, especially for metabolomics data because, as we know, it is more affected by environmental factors than for example genetic, transcriptome or proteome data.<br />
<br />
===Question 4===<br />
<br />
''' 4. As one of the people constantly working on software/packages development in R for metabolomics, could you share some recent updates that may be interesting for the community? '''<br />
<br />
This might be partially also answered by point 2 above. In addition, what we aim at present is to define an infrastructure that enables to access various reference libraries (such as spectral libraries and compound annotations from e.g., HMDB, MassBank etc) in a more standardized way. Ultimately, this should help the end user, as they would no longer loose time in converting, importing, and reformatting data. My vision would be to distribute such annotation resources in a user friendly and reproducible way. For genomic, transcriptomic and proteome annotations this is already possible through Biocondutor's AnnotationHub resource. We are now planning to do the same for metabolite or small compound annotations. In addition, we're working hard to better integrate some of these fantastic tools that are out there, like SIRIUS or MASST, into R which would enable to use them without the need to manually export, upload, execute and re-load the results again into R. <br />
<br />
===Question 5===<br />
<br />
''' 5. What tips/advices would you give for ECR who would like to start working with R in metabolomics? '''<br />
<br />
The power of R is the possibility to create flexible, customized, and reproducible analysis workflows by using and integrating methods from this huge number of packages that are out there. For that, obviously, some understanding of R is needed. For people that don't have experience with R, one of the introductory courses/workshops from Data Carpentry (https://datacarpentry.org/) might be a good starting point. Also, each R package (should) provides documents describing how it can be used based on some use-cases (the so-called package "vignettes"). It's always a good thing to first go through these to get a feeling how a package can be used and what functionality it provides. In addition, there are a lot of other tutorials and workshops out there, also for the analysis of metabolomics data, that can be used as a starting point to set up own, custom, workflows. Most importantly, don't be afraid to get in contact with the package developers if something is unclear. Most will help you out if something is not working.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Expert_Opinion&diff=1626Expert Opinion2022-03-08T05:11:05Z<p>FitriAmalia: </p>
<hr />
<div>The '''Expert Opinion''' is an initiative from the [[Early-Career Members Network|Early-Career Members Network (EMN) Committee]] that intends to publish career feedback from leading researchers in the metabolomics field. With that, early career researchers can get to know different specialists on the field and, more importantly, get insights and tips on how to build their on career.<br />
<br />
[[Image: ShuichiShimma.jpg|75px|link= Shuichi Shimma]] [[Shuichi Shimma| Dr. Shuichi Shimma (March, 2022)]]<br />
<br />
[[Image: JohannesRainer.jpeg|75px|link= Johannes Rainer]] [[Johannes Rainer| Dr. Johannes Rainer (February, 2022)]]<br />
<br />
[[Image: TimEbbels.jpg|75px|link= Tim Ebbels]] [[Tim Ebbels| Dr. Tim Ebbels (January, 2022)]]<br />
<br />
[[Image: Michael Witting.jpg|75px|link= Michael Witting]] [[Michael Witting| Dr. Michael Witting (October, 2021)]]<br />
<br />
[[Image: Candice Ulmer.jpg|75px|link= Candice Ulmer]] [[Candice Ulmer| Dr. Candice Z. Ulmer (August, 2021)]]<br />
<br />
[[Image: Kati_Hanhineva2.jpg|75px|link= Kati Hanhineva]] [[Kati Hanhineva| Dr. Kati Hanhineva (May, 2021)]]<br />
<br />
[[Image: Justine_Bertrand-Michel.jpg|75px|link= Justine Bertrand-Michel]] [[Justine Bertrand-Michel|Dr. Justine Bertrand-Michel (April, 2021)]]<br />
<br />
[[Image:Pieter_Dorrestein.jpg|75px|link= Pieter Dorrestein]] [[Pieter Dorrestein|Professor Pieter Dorrestein (March, 2021)]]<br />
<br />
[[Image:Roy_Goodacre.png|75px|link= Roy Goodacre]] [[Roy Goodacre|Professor Roy Goodacre (February, 2021)]]<br />
<br />
[[Image: Kazuki_Saito.jpg|75px|link= Kazuki Saito]] [[Kazuki Saito|Dr. Kazuki Saito (January, 2021)]]<br />
<br />
[[Image: Augustin_Scalbert.jpg|75px|link= Augustin Scalbert]] [[Augustin Scalbert|Dr. Augustin Scalbert (December, 2020)]]<br />
<br />
[[Image: Jessica_LaskySu.jpg|75px|link= Jessica Lasky-Su]] [[Jessica Lasky-Su|Associate Professor Jessica Lasky-Su (February, 2020)]]<br />
<br />
[[Image: Nichole_Reisdorph.png|75px|link= Nichole Reisdorph]] [[Nichole Reisdorph|Dr Nichole Reisdorph (September, 2019)]]<br />
<br />
[[Image:RickDunn.png|75px|link= Rick Dunn]] [[Rick Dunn|Professor Warwick (Rick) Dunn (July, 2019)]]<br />
<br />
[[Image:Mark_R_Viant.png|75px|link= Mark Viant]] [[Mark Viant|Professor Mark Viant (April, 2019)]]<br />
<br />
[[Image:StaceyReinke.jpg|75px|link= Stacey Reinke]] [[Stacey Reinke|Dr Stacey Reinke (March, 2019)]]<br />
<br />
[[Image:Antonio.jpg|75px|link= Carla Antonio]] [[Carla_Antonio|Dr Carla Antonio (July, 2018)]]<br />
<br />
[[Image:Vanderhooft.jpg|75px|link= Justin van der Hooft]] [[Justin_van_der_Hooft|Dr Justin J.J. van der Hooft (February, 2018)]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=File:ShuichiShimma.jpg&diff=1625File:ShuichiShimma.jpg2022-03-08T05:10:05Z<p>FitriAmalia: </p>
<hr />
<div></div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Main_Page&diff=1624Main Page2022-02-11T06:19:45Z<p>FitriAmalia: </p>
<hr />
<div>__NOTOC____NOEDITSECTION__{{notitle}}<div style="position: relative; top: -30px; z-index: 100; font-size:100%;"><br />
{|cellpadding="5" cellspacing="0"|<br />
<br />
|style="border: 1px solid #DDDDDD;font-size:120%"|<br />
Welcome to the '''Early-Career Members Network (EMN) Webpage''', a resource curated by [[Early-Career_Members_Network | Early-Career Members Network of the Metabolomics Society]]. This wiki-styled page is designed to be a focal point for educational resources and online tools related to all facets of metabolomics, aiming to reach mainly young researchers of the field.<br />
<br />
<!-- NOTES FOR THE CATEGORIES TABLE:<br />
<br />
* There is *NO* paragraph break after the <br /> tags, only a single space.<br />
* Do not enter empty lines anywhere between <span...> and </center> (breaks the formatting).<br />
* Images are taken from http://en.wikipedia.org/wiki/Wikipedia:Categorical_index<br />
<br />
<br />
--><br />
<span id="Highlights"></span><br />
<center><br />
<br />
{| width=90% style="border: 2px solid #DDDDDD; background-color:rgb(250,250,255); margin-top:10px" cellspacing=20<br />
!colspan=2 style="text-align:center; font-size:100%;"|'''Highlights'''<br />
|-<br />
!colspan=2 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;padding-left:1em;"|<br />
<h3><br />
[[Image: JohannesRainer.jpeg|x140px|border|link= Johannes Rainer]]<br /><br /> <br />
This month Expert Opinion comes from Dr [[Johannes Rainer| Johannes Rainer!]]<br /><br /><br />
</h3><br />
|style="width:25%; font-size:80%; vertical-align:center; text-align:center;"|<br />
<h3><br />
[[Image:Conference_2022.png|x150px|border|link=Upcoming Events]]<br /><br /> <br />
Do not miss the Metabolomics Conference 2022. Click [https://www.metabolomics2022.org/ here] to know more! <br /><br /><br />
|}<br />
<br />
<span id="Regions"></span><br />
<br />
{|width=80% style="border: 2px solid #DDDDDD; margin-top:1px" cellspacing=1;"<br />
!colspan=6 style="text-align:center; font-size:100%;"|'''Finding Metabolomics Communities'''<br />
|-<br />
!colspan=6 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:16,66%; font-size:95%; vertical-align:bottom; text-align:center;"|<br />
[[Image:128px-Blank Map-Africa.svg.png|link= Metabolomics Communities#Africa|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Africa|'''Africa''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-Location Map Asia.svg.png|link= Metabolomics Communities#Asia|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Asia|'''Asia''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:BlankMap-Europe-v4.png|link= Metabolomics Communities#Europe|x100px]]<br /><br /><br />
[[Metabolomics_Communities#Europe|'''Europe''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-America_Blank.svg.png|link=Metabolomics Communities#North and Central America|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#North and Central America|'''North & Central America''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:Blank Map Oceania3.svg.png|link=Metabolomics Communities#Oceania|x100px]]<br /><br /> <br />
[[Metabolomics_Communities#Oceania|'''Oceania''']] <br /><br /> <br />
</h3><br />
|style="width:16,66%; font-size:80%; vertical-align:bottom; text-align:center;"|<br />
<h3><br />
[[Image:128px-BlankMap-South-America.png|link= Communities#South America|x100px]]<br /><br /><br />
[[Metabolomics_Communities#South America|'''South America''']] <br /><br /> <br />
|}<br />
<br />
<span id="Keep updated! Follow us"></span><br />
{| width=90% style="border: 2px solid #DDDDDD; ; margin-top:20px" cellspacing=6<br />
!colspan=3 style="text-align:center; font-size:100%;"|'''Keep updated! Follow us on social medias!'''<br />
|-<br />
!colspan=3 style="text-align:center;"|<br />
----<br />
|-<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:right; padding-left:1em;"|<br />
[[Image: Facebook.png|70px|link=https://www.facebook.com/EMN.MetabolomicsSociety]]<br /><br /> <br />
|style="width:20%; font-size:95%; vertical-align:center; text-align:left;"|<br />
|style="width:40%; font-size:95%; vertical-align:center; text-align:left;"|<br />
[[Image:Twitter.png|70px|link=https://twitter.com/emn_metsoc?lang=pt]]<br /><br /> <br />
</h3><br />
|}<br />
If you would like to suggest content, please contact the current EMN committee at ''info.emn@metabolomicssociety.org''<br />
|}</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Johannes_Rainer&diff=1623Johannes Rainer2022-02-11T03:15:34Z<p>FitriAmalia: </p>
<hr />
<div>[[Image: JohannesRainer.jpeg|thumb| Johannes Rainer ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Johannes studied Electrical and Biomedical Engineering at the Technical University of Graz, Austria. He obtained his MSc in Bioinformatics in 2003 and after that conducted a PhD in Bioinformatics with a focus on cancer research in particular childhood leukemia. From 2007 to 2015 he was working, first as a Post Doc and then as a junior group leader for Bioinformatics, at the Medical University of Innsbruck, Austria. His main research areas during this time were transcriptomics and genomics in the field of childhood leukemia. In 2015 he moved to the Institute for Biomedicine of the Eurac Research in Bolzano, Italy and shifted his focus first on genetics and subsequently to metabolomics research. In 2018 he became the head of the Computational Metabolomics Team of the Institute for Biomedicine at Eurac Research. Johannes has a long-lasting experience in open software development in the fields of transcriptomics, genomics, and metabolomics. Since 2020 he got more involved in the Bioconductor project and is since a member of the Community Advisory Board, the Code of Conduct Committee, and the Package Review Working Group. He is author of, and contributor to more than 15 Bioconductor packages most of them providing functionality for the analysis of mass spectrometry and metabolomics data. In his free time, he enjoys designing stickers and logos, mountaineering and spending time with his family.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first got in contact with metabolomics data when I joined the Institute for Biomedicine of Eurac Research. I had long lasting experience in the analysis of large-scale data sets (mostly microarray and RNA-seq data) and was thus appointed to help analyzing the metabolomics data sets that were generated at the Institute, in particular the untargeted LC-MS data. I started investigating and looking for tools to analyze that data and had the impression that the software available at that time, especially when compared to the software for the processing of transcriptome data, was sub-optimal. This was when I then first contacted Steffen Neumann and Laurent Gatto and discussed with them the possibility to join forces to update and improve MS-related software in R. In particular, I wanted to avoid the code-duplication being present in the various software packages and to unify the code base of R/Bioconductor packages for the analysis of mass spectrometry (MS) data (both for metabolomics and proteomics). The rest is history. We've updated since the xcms and MSnbase R packages to support also the analysis of very large data sets and from there, started to implement, together with an ever-growing number of collaborators and contributors, a large panel of other software packages that together, as we believe, provide a comprehensive and flexible infrastructure for MS data handling and analysis.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Recently, we've implemented a set of R packages providing established methods and core functionality for the annotation of untargeted metabolomics data. Rather than being a single application, these packages provide modular functions that can be used to create customized, flexible, and reproducible annotation workflows. In addition, we're currently analyzing the targeted and untargeted metabolomics data sets from our in-house population study.<br />
<br />
===Question 3===<br />
<br />
''' 3. What are the main challenges you see on the data analysis of untargeted metabolomics data from populational studies? '''<br />
<br />
It's their magnitude. On one hand this data is computationally intense, but that's something we can easily work on and fix by simply implement more efficient or less memory demanding software. The bigger problem for me is that such data tends to be so large that it becomes hard to do a proper and comprehensive quality control. And that is obviously essential if we want to evaluate whether the pre-processing (peak detection, alignment, and correspondence) actually worked for all files. Another important fact, which however also applies to targeted metabolomics data, is that data from population studies will always be less controlled than for example data in case-control or clinical studies. Hence, evaluating influences of potential confounding factors is in my opinion very important, especially for metabolomics data because, as we know, it is more affected by environmental factors than for example genetic, transcriptome or proteome data.<br />
<br />
===Question 4===<br />
<br />
''' 4. As one of the people constantly working on software/packages development in R for metabolomics, could you share some recent updates that may be interesting for the community? '''<br />
<br />
This might be partially also answered by point 2 above. In addition, what we aim at present is to define an infrastructure that enables to access various reference libraries (such as spectral libraries and compound annotations from e.g., HMDB, MassBank etc) in a more standardized way. Ultimately, this should help the end user, as they would no longer loose time in converting, importing, and reformatting data. My vision would be to distribute such annotation resources in a user friendly and reproducible way. For genomic, transcriptomic and proteome annotations this is already possible through Biocondutor's AnnotationHub resource. We are now planning to do the same for metabolite or small compound annotations. In addition, we're working hard to better integrate some of these fantastic tools that are out there, like SIRIUS or MASST, into R which would enable to use them without the need to manually export, upload, execute and re-load the results again into R. <br />
<br />
===Question 5===<br />
<br />
''' 5. What tips/advices would you give for ECR who would like to start working with R in metabolomics? '''<br />
<br />
The power of R is the possibility to create flexible, customized, and reproducible analysis workflows by using and integrating methods from this huge number of packages that are out there. For that, obviously, some understanding of R is needed. For people that don't have experience with R, one of the introductory courses/workshops from Data Carpentry (https://datacarpentry.org/) might be a good starting point. Also, each R package (should) provides documents describing how it can be used based on some use-cases (the so-called package "vignettes"). It's always a good thing to first go through these to get a feeling how a package can be used and what functionality it provides. In addition, there are a lot of other tutorials and workshops out there, also for the analysis of metabolomics data, that can be used as a starting point to set up own, custom, workflows. Most importantly, don't be afraid to get in contact with the package developers if something is unclear. Most will help you out if something is not working.<br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Johannes_Rainer&diff=1622Johannes Rainer2022-02-11T03:13:14Z<p>FitriAmalia: Created page with " Johannes Rainer ==Short Biography== ''' Biography''' Johannes studied Electrical and Biomedical Engineering at the Technical Univers..."</p>
<hr />
<div>[[Image: JohannesRainer.jpeg|thumb| Johannes Rainer ]]<br />
<br />
==Short Biography==<br />
<br />
''' Biography''' <br />
<br />
Johannes studied Electrical and Biomedical Engineering at the Technical University of Graz, Austria. He obtained his MSc in Bioinformatics in 2003 and after that conducted a PhD in Bioinformatics with a focus on cancer research in particular childhood leukemia. From 2007 to 2015 he was working, first as a Post Doc and then as a junior group leader for Bioinformatics, at the Medical University of Innsbruck, Austria. His main research areas during this time were transcriptomics and genomics in the field of childhood leukemia. In 2015 he moved to the Institute for Biomedicine of the Eurac Research in Bolzano, Italy and shifted his focus first on genetics and subsequently to metabolomics research. In 2018 he became the head of the Computational Metabolomics Team of the Institute for Biomedicine at Eurac Research. Johannes has a long-lasting experience in open software development in the fields of transcriptomics, genomics, and metabolomics. Since 2020 he got more involved in the Bioconductor project and is since a member of the Community Advisory Board, the Code of Conduct Committee, and the Package Review Working Group. He is author of, and contributor to more than 15 Bioconductor packages most of them providing functionality for the analysis of mass spectrometry and metabolomics data. In his free time, he enjoys designing stickers and logos, mountaineering and spending time with his family.<br />
<br />
==Expert Opinion==<br />
===Question 1===<br />
<br />
''' 1. When and why did you start using metabolomics in your investigations?'''<br />
<br />
I first got in contact with metabolomics data when I joined the Institute for Biomedicine of Eurac Research. I had long lasting experience in the analysis of large-scale data sets (mostly microarray and RNA-seq data) and was thus appointed to help analyzing the metabolomics data sets that were generated at the Institute, in particular the untargeted LC-MS data. I started investigating and looking for tools to analyze that data and had the impression that the software available at that time, especially when compared to the software for the processing of transcriptome data, was sub-optimal. This was when I then first contacted Steffen Neumann and Laurent Gatto and discussed with them the possibility to join forces to update and improve MS-related software in R. In particular, I wanted to avoid the code-duplication being present in the various software packages and to unify the code base of R/Bioconductor packages for the analysis of mass spectrometry (MS) data (both for metabolomics and proteomics). The rest is history. We've updated since the xcms and MSnbase R packages to support also the analysis of very large data sets and from there, started to implement, together with an ever-growing number of collaborators and contributors, a large panel of other software packages that together, as we believe, provide a comprehensive and flexible infrastructure for MS data handling and analysis.<br />
<br />
===Question 2===<br />
<br />
''' 2. What have you been working on recently? '''<br />
<br />
Recently, we've implemented a set of R packages providing established methods and core functionality for the annotation of untargeted metabolomics data. Rather than being a single application, these packages provide modular functions that can be used to create customized, flexible, and reproducible annotation workflows. In addition, we're currently analyzing the targeted and untargeted metabolomics data sets from our in-house population study.<br />
<br />
===Question 3===<br />
<br />
''' 3. What are the main challenges you see on the data analysis of untargeted metabolomics data from populational studies? '''<br />
<br />
It's their magnitude. On one hand this data is computationally intense, but that's something we can easily work on and fix by simply implement more efficient or less memory demanding software. The bigger problem for me is that such data tends to be so large that it becomes hard to do a proper and comprehensive quality control. And that is obviously essential if we want to evaluate whether the pre-processing (peak detection, alignment, and correspondence) actually worked for all files. Another important fact, which however also applies to targeted metabolomics data, is that data from population studies will always be less controlled than for example data in case-control or clinical studies. Hence, evaluating influences of potential confounding factors is in my opinion very important, especially for metabolomics data because, as we know, it is more affected by environmental factors than for example genetic, transcriptome or proteome data.<br />
<br />
===Question 4===<br />
<br />
''' 4. As one of the people constantly working on software/packages development in R for metabolomics, could you share some recent updates that may be interesting for the community? '''<br />
<br />
This might be partially also answered by point 2 above. In addition, what we aim at present is to define an infrastructure that enables to access various reference libraries (such as spectral libraries and compound annotations from e.g., HMDB, MassBank etc) in a more standardized way. Ultimately, this should help the end user, as they would no longer loose time in converting, importing, and reformatting data. My vision would be to distribute such annotation resources in a user friendly and reproducible way. For genomic, transcriptomic and proteome annotations this is already possible through Biocondutor's AnnotationHub resource. We are now planning to do the same for metabolite or small compound annotations. In addition, we're working hard to better integrate some of these fantastic tools that are out there, like SIRIUS or MASST, into R which would enable to use them without the need to manually export, upload, execute and re-load the results again into R. <br />
<br />
===Question 5===<br />
<br />
''' 5. What tips/advices would you give for ECR who would like to start working with R in metabolomics? '''<br />
<br />
The power of R is the possibility to create flexible, customized, and reproducible analysis workflows by using and integrating methods from this huge number of packages that are out there. For that, obviously, some understanding of R is needed. For people that don't have experience with R, one of the introductory courses/workshops from Data Carpentry (https://datacarpentry.org/) might be a good starting point. Also, each R package (should) provides documents describing how it can be used based on some use-cases (the so-called package "vignettes"). It's always a good thing to first go through these to get a feeling how a package can be used and what functionality it provides. In addition, there are a lot of other tutorials and workshops out there, also for the analysis of metabolomics data, that can be used as a starting point to set up own, custom, workflows. Most importantly, don't be afraid to get in contact with the package developers if something is unclear. Most will help you out if something is not working.<br />
<br />
<br />
===References===<br />
1. <br />
<br />
==See also==<br />
<br />
[[Category:Expert Opinion]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Expert_Opinion&diff=1621Expert Opinion2022-02-11T03:08:05Z<p>FitriAmalia: </p>
<hr />
<div>The '''Expert Opinion''' is an initiative from the [[Early-Career Members Network|Early-Career Members Network (EMN) Committee]] that intends to publish career feedback from leading researchers in the metabolomics field. With that, early career researchers can get to know different specialists on the field and, more importantly, get insights and tips on how to build their on career.<br />
<br />
[[Image: JohannesRainer.jpeg|75px|link= Johannes Rainer]] [[Johannes Rainer| Dr. Johannes Rainer (February, 2022)]]<br />
<br />
[[Image: TimEbbels.jpg|75px|link= Tim Ebbels]] [[Tim Ebbels| Dr. Tim Ebbels (January, 2022)]]<br />
<br />
[[Image: Michael Witting.jpg|75px|link= Michael Witting]] [[Michael Witting| Dr. Michael Witting (October, 2021)]]<br />
<br />
[[Image: Candice Ulmer.jpg|75px|link= Candice Ulmer]] [[Candice Ulmer| Dr. Candice Z. Ulmer (August, 2021)]]<br />
<br />
[[Image: Kati_Hanhineva2.jpg|75px|link= Kati Hanhineva]] [[Kati Hanhineva| Dr. Kati Hanhineva (May, 2021)]]<br />
<br />
[[Image: Justine_Bertrand-Michel.jpg|75px|link= Justine Bertrand-Michel]] [[Justine Bertrand-Michel|Dr. Justine Bertrand-Michel (April, 2021)]]<br />
<br />
[[Image:Pieter_Dorrestein.jpg|75px|link= Pieter Dorrestein]] [[Pieter Dorrestein|Professor Pieter Dorrestein (March, 2021)]]<br />
<br />
[[Image:Roy_Goodacre.png|75px|link= Roy Goodacre]] [[Roy Goodacre|Professor Roy Goodacre (February, 2021)]]<br />
<br />
[[Image: Kazuki_Saito.jpg|75px|link= Kazuki Saito]] [[Kazuki Saito|Dr. Kazuki Saito (January, 2021)]]<br />
<br />
[[Image: Augustin_Scalbert.jpg|75px|link= Augustin Scalbert]] [[Augustin Scalbert|Dr. Augustin Scalbert (December, 2020)]]<br />
<br />
[[Image: Jessica_LaskySu.jpg|75px|link= Jessica Lasky-Su]] [[Jessica Lasky-Su|Associate Professor Jessica Lasky-Su (February, 2020)]]<br />
<br />
[[Image: Nichole_Reisdorph.png|75px|link= Nichole Reisdorph]] [[Nichole Reisdorph|Dr Nichole Reisdorph (September, 2019)]]<br />
<br />
[[Image:RickDunn.png|75px|link= Rick Dunn]] [[Rick Dunn|Professor Warwick (Rick) Dunn (July, 2019)]]<br />
<br />
[[Image:Mark_R_Viant.png|75px|link= Mark Viant]] [[Mark Viant|Professor Mark Viant (April, 2019)]]<br />
<br />
[[Image:StaceyReinke.jpg|75px|link= Stacey Reinke]] [[Stacey Reinke|Dr Stacey Reinke (March, 2019)]]<br />
<br />
[[Image:Antonio.jpg|75px|link= Carla Antonio]] [[Carla_Antonio|Dr Carla Antonio (July, 2018)]]<br />
<br />
[[Image:Vanderhooft.jpg|75px|link= Justin van der Hooft]] [[Justin_van_der_Hooft|Dr Justin J.J. van der Hooft (February, 2018)]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Expert_Opinion&diff=1620Expert Opinion2022-02-11T03:07:30Z<p>FitriAmalia: </p>
<hr />
<div>The '''Expert Opinion''' is an initiative from the [[Early-Career Members Network|Early-Career Members Network (EMN) Committee]] that intends to publish career feedback from leading researchers in the metabolomics field. With that, early career researchers can get to know different specialists on the field and, more importantly, get insights and tips on how to build their on career.<br />
<br />
[[Image: Johannes Rainer.jpg|75px|link= Johannes Rainer]] [[Johannes Rainer| Dr. Johannes Rainer (February, 2022)]]<br />
<br />
[[Image: TimEbbels.jpg|75px|link= Tim Ebbels]] [[Tim Ebbels| Dr. Tim Ebbels (January, 2022)]]<br />
<br />
[[Image: Michael Witting.jpg|75px|link= Michael Witting]] [[Michael Witting| Dr. Michael Witting (October, 2021)]]<br />
<br />
[[Image: Candice Ulmer.jpg|75px|link= Candice Ulmer]] [[Candice Ulmer| Dr. Candice Z. Ulmer (August, 2021)]]<br />
<br />
[[Image: Kati_Hanhineva2.jpg|75px|link= Kati Hanhineva]] [[Kati Hanhineva| Dr. Kati Hanhineva (May, 2021)]]<br />
<br />
[[Image: Justine_Bertrand-Michel.jpg|75px|link= Justine Bertrand-Michel]] [[Justine Bertrand-Michel|Dr. Justine Bertrand-Michel (April, 2021)]]<br />
<br />
[[Image:Pieter_Dorrestein.jpg|75px|link= Pieter Dorrestein]] [[Pieter Dorrestein|Professor Pieter Dorrestein (March, 2021)]]<br />
<br />
[[Image:Roy_Goodacre.png|75px|link= Roy Goodacre]] [[Roy Goodacre|Professor Roy Goodacre (February, 2021)]]<br />
<br />
[[Image: Kazuki_Saito.jpg|75px|link= Kazuki Saito]] [[Kazuki Saito|Dr. Kazuki Saito (January, 2021)]]<br />
<br />
[[Image: Augustin_Scalbert.jpg|75px|link= Augustin Scalbert]] [[Augustin Scalbert|Dr. Augustin Scalbert (December, 2020)]]<br />
<br />
[[Image: Jessica_LaskySu.jpg|75px|link= Jessica Lasky-Su]] [[Jessica Lasky-Su|Associate Professor Jessica Lasky-Su (February, 2020)]]<br />
<br />
[[Image: Nichole_Reisdorph.png|75px|link= Nichole Reisdorph]] [[Nichole Reisdorph|Dr Nichole Reisdorph (September, 2019)]]<br />
<br />
[[Image:RickDunn.png|75px|link= Rick Dunn]] [[Rick Dunn|Professor Warwick (Rick) Dunn (July, 2019)]]<br />
<br />
[[Image:Mark_R_Viant.png|75px|link= Mark Viant]] [[Mark Viant|Professor Mark Viant (April, 2019)]]<br />
<br />
[[Image:StaceyReinke.jpg|75px|link= Stacey Reinke]] [[Stacey Reinke|Dr Stacey Reinke (March, 2019)]]<br />
<br />
[[Image:Antonio.jpg|75px|link= Carla Antonio]] [[Carla_Antonio|Dr Carla Antonio (July, 2018)]]<br />
<br />
[[Image:Vanderhooft.jpg|75px|link= Justin van der Hooft]] [[Justin_van_der_Hooft|Dr Justin J.J. van der Hooft (February, 2018)]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Expert_Opinion&diff=1619Expert Opinion2022-02-11T03:06:21Z<p>FitriAmalia: </p>
<hr />
<div>The '''Expert Opinion''' is an initiative from the [[Early-Career Members Network|Early-Career Members Network (EMN) Committee]] that intends to publish career feedback from leading researchers in the metabolomics field. With that, early career researchers can get to know different specialists on the field and, more importantly, get insights and tips on how to build their on career.<br />
<br />
[[Image: JohannesRainer.jpg|75px|link= Johannes Rainer]] [[Johannes Rainer| Dr. Johannes Rainer (February, 2022)]]<br />
<br />
[[Image: TimEbbels.jpg|75px|link= Tim Ebbels]] [[Tim Ebbels| Dr. Tim Ebbels (January, 2022)]]<br />
<br />
[[Image: Michael Witting.jpg|75px|link= Michael Witting]] [[Michael Witting| Dr. Michael Witting (October, 2021)]]<br />
<br />
[[Image: Candice Ulmer.jpg|75px|link= Candice Ulmer]] [[Candice Ulmer| Dr. Candice Z. Ulmer (August, 2021)]]<br />
<br />
[[Image: Kati_Hanhineva2.jpg|75px|link= Kati Hanhineva]] [[Kati Hanhineva| Dr. Kati Hanhineva (May, 2021)]]<br />
<br />
[[Image: Justine_Bertrand-Michel.jpg|75px|link= Justine Bertrand-Michel]] [[Justine Bertrand-Michel|Dr. Justine Bertrand-Michel (April, 2021)]]<br />
<br />
[[Image:Pieter_Dorrestein.jpg|75px|link= Pieter Dorrestein]] [[Pieter Dorrestein|Professor Pieter Dorrestein (March, 2021)]]<br />
<br />
[[Image:Roy_Goodacre.png|75px|link= Roy Goodacre]] [[Roy Goodacre|Professor Roy Goodacre (February, 2021)]]<br />
<br />
[[Image: Kazuki_Saito.jpg|75px|link= Kazuki Saito]] [[Kazuki Saito|Dr. Kazuki Saito (January, 2021)]]<br />
<br />
[[Image: Augustin_Scalbert.jpg|75px|link= Augustin Scalbert]] [[Augustin Scalbert|Dr. Augustin Scalbert (December, 2020)]]<br />
<br />
[[Image: Jessica_LaskySu.jpg|75px|link= Jessica Lasky-Su]] [[Jessica Lasky-Su|Associate Professor Jessica Lasky-Su (February, 2020)]]<br />
<br />
[[Image: Nichole_Reisdorph.png|75px|link= Nichole Reisdorph]] [[Nichole Reisdorph|Dr Nichole Reisdorph (September, 2019)]]<br />
<br />
[[Image:RickDunn.png|75px|link= Rick Dunn]] [[Rick Dunn|Professor Warwick (Rick) Dunn (July, 2019)]]<br />
<br />
[[Image:Mark_R_Viant.png|75px|link= Mark Viant]] [[Mark Viant|Professor Mark Viant (April, 2019)]]<br />
<br />
[[Image:StaceyReinke.jpg|75px|link= Stacey Reinke]] [[Stacey Reinke|Dr Stacey Reinke (March, 2019)]]<br />
<br />
[[Image:Antonio.jpg|75px|link= Carla Antonio]] [[Carla_Antonio|Dr Carla Antonio (July, 2018)]]<br />
<br />
[[Image:Vanderhooft.jpg|75px|link= Justin van der Hooft]] [[Justin_van_der_Hooft|Dr Justin J.J. van der Hooft (February, 2018)]]</div>FitriAmaliahttp://wiki.metabolomicssociety.org/index.php?title=Expert_Opinion&diff=1618Expert Opinion2022-02-11T03:05:43Z<p>FitriAmalia: </p>
<hr />
<div>The '''Expert Opinion''' is an initiative from the [[Early-Career Members Network|Early-Career Members Network (EMN) Committee]] that intends to publish career feedback from leading researchers in the metabolomics field. With that, early career researchers can get to know different specialists on the field and, more importantly, get insights and tips on how to build their on career.<br />
<br />
[[Image: TimEbbels.jpg|75px|link= Johannes Rainer]] [[Johannes Rainer| Dr. Johannes Rainer (February, 2022)]]<br />
<br />
[[Image: TimEbbels.jpg|75px|link= Tim Ebbels]] [[Tim Ebbels| Dr. Tim Ebbels (January, 2022)]]<br />
<br />
[[Image: Michael Witting.jpg|75px|link= Michael Witting]] [[Michael Witting| Dr. Michael Witting (October, 2021)]]<br />
<br />
[[Image: Candice Ulmer.jpg|75px|link= Candice Ulmer]] [[Candice Ulmer| Dr. Candice Z. Ulmer (August, 2021)]]<br />
<br />
[[Image: Kati_Hanhineva2.jpg|75px|link= Kati Hanhineva]] [[Kati Hanhineva| Dr. Kati Hanhineva (May, 2021)]]<br />
<br />
[[Image: Justine_Bertrand-Michel.jpg|75px|link= Justine Bertrand-Michel]] [[Justine Bertrand-Michel|Dr. Justine Bertrand-Michel (April, 2021)]]<br />
<br />
[[Image:Pieter_Dorrestein.jpg|75px|link= Pieter Dorrestein]] [[Pieter Dorrestein|Professor Pieter Dorrestein (March, 2021)]]<br />
<br />
[[Image:Roy_Goodacre.png|75px|link= Roy Goodacre]] [[Roy Goodacre|Professor Roy Goodacre (February, 2021)]]<br />
<br />
[[Image: Kazuki_Saito.jpg|75px|link= Kazuki Saito]] [[Kazuki Saito|Dr. Kazuki Saito (January, 2021)]]<br />
<br />
[[Image: Augustin_Scalbert.jpg|75px|link= Augustin Scalbert]] [[Augustin Scalbert|Dr. Augustin Scalbert (December, 2020)]]<br />
<br />
[[Image: Jessica_LaskySu.jpg|75px|link= Jessica Lasky-Su]] [[Jessica Lasky-Su|Associate Professor Jessica Lasky-Su (February, 2020)]]<br />
<br />
[[Image: Nichole_Reisdorph.png|75px|link= Nichole Reisdorph]] [[Nichole Reisdorph|Dr Nichole Reisdorph (September, 2019)]]<br />
<br />
[[Image:RickDunn.png|75px|link= Rick Dunn]] [[Rick Dunn|Professor Warwick (Rick) Dunn (July, 2019)]]<br />
<br />
[[Image:Mark_R_Viant.png|75px|link= Mark Viant]] [[Mark Viant|Professor Mark Viant (April, 2019)]]<br />
<br />
[[Image:StaceyReinke.jpg|75px|link= Stacey Reinke]] [[Stacey Reinke|Dr Stacey Reinke (March, 2019)]]<br />
<br />
[[Image:Antonio.jpg|75px|link= Carla Antonio]] [[Carla_Antonio|Dr Carla Antonio (July, 2018)]]<br />
<br />
[[Image:Vanderhooft.jpg|75px|link= Justin van der Hooft]] [[Justin_van_der_Hooft|Dr Justin J.J. van der Hooft (February, 2018)]]</div>FitriAmalia